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The National Institute for Health and Care Excellence clinical guidelines, together 
with the global consensus document ‘Brain Health’, acknowledge that modification of 
lifestyle factors contribute to the holistic care of people with Multiple Sclerosis (MS). While 
people with MS often report stressful life events as a precursor to developing MS, and despite 
increasing evidence of perceived stress as a risk factor for disease activity, the evidence for 
effectively managing stress in this population is limited. This study examined the effect of an 
educational program that incorporates progressive muscle relaxation (PMR), meditation and 
mindfulness exercises (ME) on people with MS over a six-month period. 
 100 people with relapsing remitting MS were randomly assigned to receive either 
stress management education (SME) or wait list (WL). The SME group received four one-on-
one sessions during which they learned PMR, meditation and ME and were asked to perform 
these 5-7 days of the week for six months. The primary outcome measure was change in 
perceived stress as measured by: the stress Visual Acuity Scale (sVAS), the stress component 
of the Depression, Anxiety and Stress Score (DASS21), and salivary cortisol levels. The 
secondary outcome measure was change in quality of life as measured by the Multiple 
Sclerosis International Quality of Life Questionnaire (MusiQoL).  
 None of the parameters evaluated changed between pre-and post SME (p<0.05). 
These results indicate that SME does not significantly improve levels of stress or quality of 
life in people with MS.  In contrast to previous research this study suggests there is no 
association with the study intervention in reducing perceived levels of stress. Future studies 
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SETTING THE SCENE: THE RESEARCH IN CONTEXT 
1.0 Introduction to the Study 
Multiple Sclerosis (MS) is a complex neurological disorder that is not yet entirely 
understood. In Australia there are around 23,000 people with MS and it is considered the 
most common neurological disorder in young Australians (MSAustralia, 2005). Incidence 
and prevalence of MS are rapidly increasing, and the gender ratio is increasing for women, at 
3:1 female to male being diagnosed (Ribbons, Lea, Tiedeman, Mackenzie, & Lechner-Scott, 
2017).  There is evidence to support that MS is an immune cell mediated disease leading to 
destruction of myelin and axons within the central nervous system (Haines, Inglese, & 
Casaccia, 2011). It is likely that people with a genetic predisposition for MS encounter 
environmental exposure/s that trigger immune attack on myelin, the fatty protein that protects 
nerve fibres, reducing conduction of nerve impulses along the neurones. The result is acute, 
localised inflammation, scarred myelin and damaged or destroyed axons. This presents as 
clinical attacks and transient or permanent clinical dysfunction depending on location 
resulting in sensory, motor, autonomic, mood or cognitive difficulties. Over time people with 
MS often experience fewer acute inflammatory attacks and accumulate increasing disability.  
Comprehensive care practices that maximise positive outcomes for people with MS have 
been steered by evidenced based practice, which includes the recently updated National 
Institute for Health and Care Excellence (NICE) clinical guidelines and the international 
consensus document, Brain Health: Time Matters in Multiple Sclerosis (Giovannoni et al., 
2016) . Both these documents promote early access to treatment and comprehensive review 
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by MS specialists, focusing on chronic disease modifiable lifestyle factors (Giovannoni et al., 
2016). Well established modifiable lifestyle factors include low levels of Vitamin D3, and 
childhood obesity. These factors are known to contribute to disease onset and progression 
(Ascherio, Munger, & Simon, 2010; Langer-Gould, Brara, Beaber, & Koebnick, 2013). The 
role of stress in disease onset and the ongoing effect of perceived stress on the course of MS 
has only recently been studied in more detail (Mohr, Hart, Julian, Cox, & Pelletier, 2004).  
There are varied approaches on how to manage perceived stress, and its impact on disease 
activity is under investigation. This project attempts to add to current knowledge of the 
management of perceived stress by using objective and subjective data measures.  
1.1 Background to the Study 
 The scope of what is now known about MS has evolved from those early writings to 
encompass disease pathophysiology and heritability. It is generally agreed to be a disorder of 
the immune system, and likely to be influenced by environmental factors. In 2013 the 
International Multiple Sclerosis Genetics Consortium identified over 150 genetic variants that 
are associated with MS (International Multiple Sclerosis Genetics et al., 2011). 
Various external and internal factors have also been identified as influential to the 
disease course: for example, the ability to emotionally adapt to receiving a diagnosis of MS 
and the ability to cope with the chronicity of MS. External factors include access to health 
care providers, supportive carers and family members, and remaining actively engaged in 
employment (Dennison, Moss-Morris, & Chalder, 2009).  There is evidence to support the 
view that increased stress can lead to depression, anxiety, poor coping skills, reduced quality 
of life, lack of social connectedness and poor self-efficacy for people with MS (Hughes, 
Robinson-Whelen, Taylor, & Hall, 2006).  
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Exposure to major negative stressful life events may increase the risk of new or 
enlarging transverse relaxation time T2 lesions which can be viewed on MRI up to 2 months 
after exposure to the event (Burns, Nawacki, Kwasny, Pelletier, & Mohr, 2014).  The Burns’ 
study hypothesised that perceived stressful life events occurring in the period leading up to 
MRI predicted acute new lesion accumulation, as measured by Gadolinium enhancement and 
number of new T2 lesions on MRI. Participants were followed up for 48 weeks and assigned 
to either an intervention group of stress management or wait list group.  121 people with MS 
completed regular MRI assessments, documentation and assignation of potential stressful life 
events using The Life Events List (LEL) every 4 weeks. Study participants also completed 
the Brief Inventory of Perceived Stress (BIPS), the Hospital anxiety and Depression Scale 
(HADS-A) and the Centre for Epidemiological Studies Depression Scale (CES-D). Negative 
stressful events were aggregated from responses that were “slightly bad” to “very bad” and 
positive stressful events were aggregated from responses that were “slightly good” to “very 
good”. Events were considered major if there was a perceived physical threat to the person 
with MS (PwMS) or someone close to them. The randomly assigned stress management 
group were treated by a clinical psychologist or social worker using a specific therapist 
manual for managing stress in MS; this programme addressed five core skills of problem 
solving, relaxation, engagement in positive activities, cognitive restructuring and increasing 
social support in addition to optional comorbidity treatment of depression or MS 
symptomatology. This 16-session intervention took place over 20-24 weeks.  The control 
group were provided with usual treatment for 40 weeks and then offered the option of 
attending a stress management workshop. Results of the Burns’ et al. study showed that 
moderate to major negative stressful events did not influence Gadolinium enhanced lesions. 
Major negative stressful events did increase risk for Gadolinium enhanced on MRI, with an 
odds ratio of 1.77 for each additional major negative stressful event. Positive stressful events 
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reduced new or enlarging T2 lesions on MRI overall, diminishing with the number of positive 
stressful events (OR 0.53). The stress management intervention used resulted in a reduced 
risk for new or enhancing lesions but also fewer participants reported negative stressful 
events, reducing the chance of a causal relationship. Despite this, one of the conclusions 
drawn by Burns’ et al. that the stress management intervention may have improved the 
participants’ ability to cope with stressful events, and perhaps to a larger degree, helped 
PwMS to avoid stressful events altogether. The study was robustly designed and bias was 
well considered, leading from a previous, related study (Mohr et al., 2012). The intervention 
programme was delivered by qualified clinicians and data collection was maximised by 
regular data collection and objective in nature (regular MRI and assessed by blinded 
neurologists). The favourable outcome is enhanced by these characteristics. However, in 
clinical environments these resources are frequently unavailable to PwMS; either due to high 
cost, health service limitations or geographical location. From a translational perspective, this 
study intervention needs to be tested under the more likely scenario of treatment delivered by 
non-psychologists and in fewer sessions.   
Managing stress might positively affect MS progression; is the conclusion made by 
several investigators of studies examining the role of stress management small populations of 
people with MS and the summary of the literature reviewed for this project. Relaxation 
breathing and PMR twice daily over 8 weeks (Artemiadis et al., 2012), PMR daily for 2 
months (Ghafari et al., 2009),  a 16 session MS specific stress management programme over 
2 months (Mohr et al., 2012), 8 sessions of mindfulness-based stress reduction (MBSR) 
strategies (Kolahkaj & Zargar, 2015), a 6 session stress self-management workshop (Hughes 
et al., 2006) and cognitive behavioural therapy  (CBT) combined with progressive deep-
muscle relaxation (F. W. Foley, Bedell, LaRocca, Scheinberg, & Reznikoff, 1987) have all 
been shown to reduce perceived stress in people with MS. Each of these studies used small 
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cohorts of PwMS, short lasting face to face interventions and relied on subjective assessments 
to measure levels of stress. Each of these studies will be critically reviewed in the following 
chapter.  
  In the Hunter New England Local Health District, the model of care for PwMS 
is a health promotion model of routine outpatient follow-up after diagnosis, and 
outpatient management of relapses and disease progression, with the aim of avoiding 
inpatient stays as much as possible. PwMS are encouraged to participate in their care as 
key stakeholders, for example by choosing and managing prophylactic treatment. This 
approach to disease management is not unique to MS but does promote adjustment to a 
diagnosis of a chronic illness. Taking control reduces hospitalisations and improves 
adherence to treatment (Beach, Keruly, & Moore, 2006; Lorig et al., 1999). 
Furthermore, health promotion activities, for example wellness programmes and 
clinical intervention programmes in MS, have been shown to have long term benefits in 
self-efficacy and health related quality of life (HRQoL) (Kuspinar, Rodriguez, & 
Mayo, 2012; Minden et al., 2013).   
The Hunter New England Local Health District employs a holistic health care 
model, and in addition to the patient, the team consists of MS nursing and medical 
specialists, with streamlined referral networks that include rehabilitation, allied health, 
psychiatry, psychology and pain management. The MS nurse specialist is often the first 
resource to contact considering new symptoms, difficulty managing existing 
symptoms, educational and employment advocacy and prophylactic therapy 
management. The role of this specialist nurse is to educate and counsel people with 
MS, triage new or worsening symptoms and work collaboratively with other health 
professionals who work with this population of people. The MS nurse specialist is 
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therefore well placed to deliver health promotion activities and assess, educate and 
evaluate basic stress management strategies.     
 This current research will evaluate the effectiveness of a nurse-led interventional 
programme of stress management in a cohort of people diagnosed with MS from the Hunter 
New England Local Health District of NSW. The interventional programme will consist of 
education and counselling in stress management techniques.  
1.2 Significance of the Study 
 Despite considerable literature describing stress in MS there are few studies that have 
evaluated stress management programmes (Artemiadis et al., 2012; F. W. Foley et al., 1987; 
Ghafari et al., 2009; Kolahkaj & Zargar, 2015; Mohr et al., 2012). Each of these stress 
management studies have used psychology or psychiatry clinicians to assess and counsel on 
stress and stress management; none utilise the MS specialist nurse (MSSN) in engaging or 
counselling PwMS. The studies have largely used self-rating assessments of the 
interventions, lacking objective examination of the intervention effect. This project aims to 
use and enhance the existing nurse-patient relationship to educate PwMS about the role of 
stress in MS, teach basic stress management strategies, and assess intervention effect in both 
objective and subjective assessments, all in the ambulatory, self-management model of care 
familiar in the Australian setting. 
A recent systematic review of stress management interventions in MS highlighted the 
need for larger (multicentre) prospectively designed studies, using biological and clinical 
measures of disease (Reynard, Sullivan, & Rae-Grant, 2014). The review sought to identify 
and evaluate the efficacy of stress management interventions in the MS population. Of the 
117 studies that were identified, only 8 were considered of robust study methodology, design 
and analysis. Closer review of the 8 studies showed likely efficacy of stress management 
7 
 
interventions but variable study design with limitations. The main limitations included lack of 
biological and clinical markers of efficacy, and small, single centre studies.  As a result, this 
current single centre study sought to redress the issue of biological markers of intervention 
efficacy by introducing salivary cortisol examination.  This current study employed a robust 
prospective randomised, case control design and used both objective and self-rating tools 
assessing outcome to contribute meaningful evidence to the stress management in MS 
discussion.   
Access to care for people with MS can be difficult owing to the cost of private care, 
long waiting lists for public service provision and geographical obstacles of distance to care 
providers. However, collaborative care, incorporating both medical and psychological care of 
individuals presenting with psychological issues, has increased, with improved access and 
reduced waiting time for people to receive care.  A study that surveyed over 3000 PwMS 
found that 60% of this group had experienced mental health issues and of this group those 
who had better mental health outcomes had received mental health care delivered by mental 
health specialists in the same facility as their MS care providers (Minden et al., 2013). 
Additionally, enhanced care is being achieved by utilising other health professionals 
(including nurses) in providing front line care in a collaborative model of care to people 
experiencing chronic illness, including mental health issues (Knowles, Chew-Graham, 
Adeyemi, Coupe, & Coventry, 2015). 
MS nurses have regular and routine contact with people with MS, especially at the 
beginning of the disease, when a diagnosis is being made, when new symptoms occur or 
when a patient is struggling to cope with MS-related issues. The nurse and patient can 
quickly develop a strong rapport as the nurse becomes a positive avenue of information and 
support  (Forbes & While, 2009)  that encompasses education, counselling and advocacy.  
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 Experienced MS specialist nurses have considerable post-graduate knowledge about 
MS; often navigating the sometimes subtle and subjective nature of disease relapses and 
transient symptomatology.  MS nurse specialists often informally educate about and promote 
stress management to people with MS. This project will provide more insight in the MS nurse 
specialist role and will promote MS nurse-led interventions and research. 
 The previous studies examining this phenomenon have been limited in 
methodological design (Reynard et al., 2014). This study adds objective evidence to the 
complement of measurements in assessing the effect of stress management strategies on 
perceived stress in MS. Salivary cortisol is a measure of stress response, collected at baseline 
and at follow up one month after intervention commencement. None of the other studies have 
attempted to include this objective bio marker of stress levels. 
1.3 Theoretical Framework 
 The terms stress and stressor were arguably first introduced by Hans Selye in 1936  
(Jackson, 2014). Although he wasn’t the first researcher of the time to investigate responses 
to external stimuli, Selye contributed significantly to the knowledge of physiological changes 
in people when experiencing a stressful event. Selye defined stress as ‘the non-specific result 
of any demand upon the body, be the effect mental or somatic’(Selye, 1956) and describes a 
stressor as a biological response of the body rather than a stimuli initiating response.  Selye 
conceived the phrase ‘general adaptation syndrome’ (GAS), which he used to characterise the 
pattern of biological response to stressors: initial alarm phase, resistance or adaptation, 
followed by exhaustion or death (Selye, 1950). This theoretical framework reflected his 
contemplations as a medical student interacting with people experiencing chronic conditions; 
that these people had a commonality in that they “looked and felt sick” (Jackson, 2014). 
Human studies followed animal studies, initially focusing on the adrenal system in mediating 
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response to external stimuli. Selye and colleagues further outlined the adaptive (or 
maladaptive) physiological response to stress using the GAS. As hormonal changes play a 
pivotal role as products and by products of the GAS, Selye resolved that a maladaptive 
response to stressors can lead to disease states (Jackson, 2014).  
 Influential to the concept of GAS was the work of Walter Cannon. In 1915 Cannon 
described the biological regulatory balance between the autonomic nervous system and the 
endocrine system (Dusek & Benson, 2009). He employed the terms ‘homeostasis’ and ‘fight 
or flight’ as parts of the acute stress response to describe the constant adjustment to 
environmental change, and the body’s acute reaction to severe or sudden threat (Dusek & 
Benson, 2009). The theories of acute stress response and the GAS support each other as 
foundations of the biological response to stressors.  
 Criticisms of this GAS theory argue that this model ignores the impact of 
psychological and environmental factors. It postulates that response is automatic, irrespective 
of the individual’s cognitive appraisal of the stressor (Tennes & Kreye, 1985). It also does 
not account for variability in personality. For example, some people relish the opportunity to 
speak publicly, others loath it. Despite the criticisms of the GAS, Selye’s conceptualisation of 
the humoral adaptive response to stress it remains the foundation for modern models of stress 
response and stress management in chronic disease.  
In addressing the lack of cognitive appraisal of stress Lazarus and Folkman in 1986  
shifted the emphasis of the biological to the cognitive domain and proposed a theoretical 
model of stress, appraisal and coping that has been empirically tested in chronic disease, 
including MS (Pakenham, 1999). Lazarus and Folkman conceptualised that responses to 
stress induce a subjective appraisal of the stress event, which would then influence coping. 
This appraisal response model is further characterised as primary appraisal and secondary 
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appraisal; primary appraisal refers to the assessment of the stressor significance (‘is this 
important to me?’); secondary appraisal refers to the assessment of one’s ability to control the 
stressor and /or resources available to manage the stressor (Folkman, Lazarus, Gruen, & 
DeLongis, 1986).  In situations where a person feels the stressor is not important it is less 
likely to cause distress. Equally, if the person feels the stressor is important to them but they 
have the ability to manage or control the stressor (or their response to the stressor) they are 
also likely to experience less distress.  In this way, positive appraisal of a stress event can 
drive effective coping and well-being. Lazarus (1966) also proposed that stress and coping 
are reciprocals of each other, in that effective coping equalled controlled stress and 
ineffective coping leads to increased stress.  The model of stress and coping is used to guide 
this study of stress management in MS.  
1.4 Research Questions 
This study will address the following three research questions: 
1. Can a stress management intervention reduce perceived stress in people with MS?  
2. Can a stress management programme improve quality of life with people with MS?  
3. Can the effect of stress management intervention be maintained beyond the intervention 
programme? 
1.5 Aims of the Study 
 The Managing Stress in MS (MindS) study was designed as a true or classic 
experimental, randomised control trial, prospectively planned for a pre-test, post-test method. 
This study design using objective (salivary cortisol evaluation) and subjective measures  
(Depression, Anxiety and Stress Scale or DASS21 and the Multiple Sclerosis International 
Quality of Life Scale or MusiQoL) was employed in order to understand the intervention's 
effect in the context of complex human phenomenon being studied, and to address the lack of 
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objective examination of intervention effect identified in the literature  (Reynard et al., 2014). 
A further objective of this study was to explore the effectiveness of this intervention in the 
context of self-managed strategies for a known risk factor for increased MS disease and 
barriers to effective implementation of these strategies. Electronic databases PubMed, Ovid, 
CINAHL, Proquest, Medline/Medline Plus and psychINFO were searched for the key terms 
multiple sclerosis and stress, stress management in multiple sclerosis, mindfulness, relaxation 





















CHAPTER 2  
 LITERATURE REVIEW 
2.0 Introduction 
Articles examining stress management interventions in populations of people with MS 
and using a randomised control trial design were included in this review. All studies included 
were prospective in design and all required informed consent from both case and control 
participants. Participants included in these studies had confirmed diagnosis of MS, were 
frequently described as stable on disease modifying therapy (DMT) and Expanded Disability 
Severity Score (EDSS) was often described as part of the demographics of the study cohorts 
but not used as an outcome measure. 
2.1 Multiple Sclerosis 
 Symptoms of MS were first described in the 14th century when Lidwina (the Virgin) 
of Schiedam in the Netherlands, fell while ice skating and went on to develop visual 
disturbance, weakness and pain (Murray, 2004). It is reported that Lidwina experienced 
relapses and remissions of her illness over the course of her life and went on to become the 
patron saint of figure skating and sickness (Orrell, 2005). Despite the work of Robert 
Carswell, who associated the presence of MS lesions with the disease, and Jean Cruveilhier, 
who described clinical symptoms in a person who subsequently went on to develop MS, it 
was not until 1868 that the disease was given a name,’ la sclerose en plaques’ or Multiple 
Sclerosis, by Jean-Martin Charcot.  Charcot is closely associated with MS because he was the 
first to correlate symptomatology with the anatomical pathophysiology. He also described the 
differences between MS and other nervous disorders such as Parkinson’s Disease (Kumar, 
Aslinia, Yale, & Mazza, 2011).  
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The disease mechanism of MS is understood to be a breakdown of the blood brain 
barrier, allowing activated immune cells to cross into the central nervous system and attack 
myelin tissue, an insulating barrier around the axons. This damage slows or interrupts 
neuronal conduction clinically inducing area-specific dysfunction. Examples of this 
dysfunction are optic neuritis, limb weakness (motor system) and paraesthesia (sensory 
system) but also bladder dysfunction or difficulties with concentration. Factors influencing 
MS prognosis include age at onset, disease course, lesion load on magnetic resonance image 
(MRI), and time to second and subsequent relapses (Moreau & Confavreux, 2000).  
 MS can be divided into relapsing remitting (RRMS), secondary progressive (SPMS) 
and primary progressive (PPMS) subtypes. Clinically isolated syndrome (CIS) defines an 
initial demyelinating event that can be a differential diagnosis to MS, but more frequently 
represents the first attack of MS (Thompson et al., 2017). RRMS is the most commonly 
diagnosed form (80-85%) (Ebers, 2004) and features periods of remission between acute 
attacks of inflammation. This inflammation is the focus of available therapy and best 
response is seen where treatment is commenced early (Mahurkar, Suppiah, & O'Doherty, 
2013). Patients with RRMS can progress to SPMS which is characterised by fewer acute 
relapses and a gradual progression in disability. The time of onset of SPMS is influenced by 
age at onset of disease (Koch, Uyttenboogaart, van Harten, & De Keyser, 2008).  Lastly 
PPMS features a continual increase in disability from onset without acute relapses (Ebers, 
2004). No treatment has shown efficacy in this disease course. 
 Despite there being currently ten therapies available for MS, no therapy cures MS. 
Treatments are taken life long and adherence to therapies in this population of people is 
variable (Locklear, 2015; Wong, Gomes, Mamdani, Manno, & O'Connor, 2011) Treatments 
for MS can be categorised into first, second and third line therapies. The first line therapies 
include beta interferon (Avonex, Betaferon, Plegridy and Rebif) and glatiramer acetate 
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(Copaxone). These therapies modulate the immune system, have moderate efficacy but a long 
standing, relatively safe profile (Wingerchuk & Carter, 2014). All are administered by self-
injection. Common side effects include localised injection site reactions and cold and flu-like 
symptoms (Wingerchuk & Carter, 2014). More recently a pegylated version of interferon 
(Plegridy) has been introduced to the market, reducing the frequency of injections but 
carrying similar side effects. Second line therapies are orally administered and frequently 
well tolerated. They include teriflunamide (Aubagio), fingolimod (Gilenya) and dimethyl 
fumarate (Tecfidera). While there are limited head to head studies comparing these newer 
therapies to the injectables it is likely they have similar or better effect. (Cohen et al., 2010; 
Fox & Rhoades, 2012) For more moderate to aggressive disease natalizumab (Tysabri) and 
alemtuzumab (Lemtrada) are frequently used. These more effective therapies are considered 
immunosuppressive and bring related side effects that need to be regimentally monitored.  
The goal for treating MS is to reduce future risk for relapse and minimise future disability. 
This treatment goal is referred to as NEDA or No Evidence of Disease Activity. NEDA can 
be demonstrated by no new lesions on magnetic resonance imaging (MRI), no clinical attacks 
of MS and no progression of neurological disability as measured by the EDSS (Giovannoni et 
al., 2015).  Whilst mainstream medicine focusses on reducing future MS disease by starting 
one of these therapies at the time of diagnosis and actively monitoring PwMS for new 
disease, most clinicians recognise that prophylactic therapy is only one aspect of managing 
MS. The other factors that can be managed, often called modifiable lifestyle factors, actively 
involve the PwMS and have been shown to affect the MS disease course and experience of 
MS, either directly or indirectly. These factors include getting regular exercise, eating a well-
balanced diet, avoiding smoking and managing stress (D'hooghe, Nagels, Bissay, & De 
Keyser, 2010).  
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MS is diagnosed according to the revised McDonald criteria (Polman et al., 2011). 
Evidence of demyelination over time and space is required to make a diagnosis of MS. A 
clinician examining a patient for MS will use clinical history, neurological examination and 
MRI as primary tools for disease diagnosis and disease progression or stability. Lesion load, 
location and clinical symptomatology can to some extent predict disease progression 
(Fernández, 2013). For example, disability progression can be predicted by a greater number 
of lesions, poor recovery from relapses and spinal cord and brainstem relapses (Jokubaitis et 
al., 2016) 
 The generally-held consensus about the pathogenesis is that MS is autoimmune in 
nature. MS likely occurs in people who are genetically predisposed and who are exposed to 
various environmental factors which trigger an immunological change (Comabella & 
Khoury, 2012). Among the identified environmental risk factors are low vitamin D levels, 
exposure to Epstein - Barr virus (EBV) (Zivadinov et al., 2009) and nicotine smoking (Salzer 
et al., 2013).  
2.2 Stress in Multiple Sclerosis 
 Another environmental factor for consideration is stress. The role of stress in MS has 
been studied at length. Stressful life events at or around the time of relapse is reported to 
bring a five-fold increased risk of relapse (Mitsonis et al., 2008; Saul et al., 2016). Stress is 
succinctly described by Jose Sa (2008) as the presence of a change in life, where the 
readjustment to change surpasses the ability to cope. This definition is all the more complex 
considering that stress is for each person tolerated and responded to differently (Goretti, 
Portaccio, Zipoli, Razzolini, & Amato, 2010). Hans Selye was one of the first to investigate 
the pathophysiology of stress, studying the response to stress since the 1930’s (Selye, 2013). 
His General Adaptation Syndrome (GAS), originally published in 1950, proposed that 
stressors produce complex physical, chemical and/or psychological changes, and are 
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subcharacterised in three stages: alarm reaction, resistance and exhaustion (Selye, 1956). He 
postulated that response to stress is affected by genetics and is highly adaptive. Furthermore, 
Selye coined the term ‘stressor’ to mean the perceived threat that triggers the response to 
stress (Szabo, Tache, & Somogyi, 2012). 
 Before examining the role that stress plays in MS, it is important to review the usual 
biological response to stress in more detail. Responding to a perceived stressful event 
involves a highly complex biological series of steps. In a normally functioning body response 
to perceived stress is managed by the hypothalamic-pituitary-adrenal (HPA) axis and the 
autonomic nervous system (Gold et al., 2005). This complex system is managed by the 
immune, endocrine and nervous system and is acutely responsive and adaptive (Deckx, Lee, 
Berneman, & Cools, 2013).  It has been suggested that neuro-endocrine-immunological 
homeostasis interruption may lead to a higher risk for autoimmune disease (Deckx et al., 
2013). Smith & Vale (2006) describe the physiological response to a perceived emotional or 
physical threat: the hypothalamus releases corticotropic releasing factor (CRF), in turn 
stimulating the pituitary gland to release adrenocorticotropic hormone (ACTH), which then 
leads to the adrenal gland releasing epinephrine, norepinephrine, catecholamine and 
glucocorticoid. The resultant hormonal surge allows for an acute response by the person to 
the stressor or stressful event and maintenance of an activated alert state until the perceived 
threat diminishes.  Additionally, the HPA axis has an effect on a wide range of physiological 
processes other than the immune response. These include digestion, emotional response, 
energy metabolism and sexual function (Du & Pang, 2015). 
 The animal model of MS, experimental autoimmune encephalitis (EAE) has been 
used for 80 years to hypothesise a raft of neuro-immunological disease features including 
histopathology, neurobiology and effect of therapeutic agents (Gold, Linington, & Lassman, 
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2006). It has been proposed that an under responsive HPA axis increases susceptibility for 
EAE (Gold et al., 2005).  
One of the more recently proposed mechanisms for HPA axis dysregulation relates to 
hyperactivity of the HPA axis, leading to increasing MS severity (Gold et al., 2005). In MS 
HPA axis dysregulation has been shown to negatively affect cognition, disease course and 
mood (Heesen, Gold, Raji, Wiedemann, & Schulz, 2002), this correlation is less clear for the 
role of HPA axis dysregulation has in MS fatigue; the Heesen (2002) study of 40 PwMS 
found no correlation of altered HPA axis effect on fatigue. Whereas in contrast, a similar-
sized but prospective study of 31 people with MS found a significant correlation of HPA axis 
dysfunction, evidenced by high ACTH levels in their study population (Gottschalk et al., 
2005). Obvious discrepancies between the studies and acknowledged by Gottschalk is the 
difference in MS type (RRMS versus mostly progressive MS) and treatment (mostly 
treatment naïve versus current therapy-exposed).  From a neuroimmunological position both 
factors are likely to affect normal HPA axis function. 
 HPA dysregulation may be correlated with the MS clinical course. Kümpfel et al. 
(2014) found elevated cortisol levels in plasma samples in a group of 60 MS patients with 
active disease and in 29 healthy controls. These levels were mildly elevated in RRMS 
patients and significantly elevated in PPMS patients. Longer term accumulated HPA 
dysregulation was confirmed in their follow up study. Additionally, but not significantly, 
higher levels of HPA axis hyperactivity was associated with untreated RRMS patients when 
compared to the DMT treated population. A limitation of that study is that while those treated 
with corticosteroids for relapse were excluded, eight of the 40 in the treatment group received 
monthly corticosteroids as prophylactic therapy. Despite this the authors have proposed a 
novel mechanism of HPA axis longitudinal dysregulation, which should be evaluated in a 
larger study with stricter inclusion criteria. 
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 One’s ability to cope with stressful events can be influenced by one’s perception of 
the ability to control the stressor or stress event. This is referred to as locus of control and can 
be either internally or externally-driven (José Sá, 2008).  An external locus of control occurs 
when one perceives that external influences like luck or fortune determine life events. In 
contrast, an internal locus of control occurs when one believes they are in control of life 
events and can alter outcomes (Vuger-Kovacić, Gregurek, Kovacić, Vuger, & Kalenić, 2007).  
These opposing positions are further influenced by one’s approach in coping with stress. It is 
generally understood that a problem-focused approach is more likely to reduce stress than an 
emotion-focused approach (Barlow, Turner, Edwards, & Gilchrist, 2009; Dennison, Yardley, 
Devereux, & Moss-Morris, 2011).  
 The overall incidence of stress occurring in MS has been reported as being as high as 
96% (Buljevac et al., 2003). Examples of stress in MS can be adjusting to the diagnosis of 
MS, to an acute relapse or change in social support. All of this can bring on chronic stress and 
lead to anxiety and/or depression (MSTrust, 2012). Stress is, of course, not limited to disease 
but includes other life stressors. Family and relationship stress, and financial stress are but 
two examples.   
 Despite the lack of robust evidence, people with MS and their carers link stressful life 
events with MS disease activity (Brown, Tennant, Dunn, & Pollard, 2005). Conducting 
studies examining the effect of stress in MS are notoriously difficult because of the complex 
nature of stress, study trial design and the lack of objective measurement of stress (Heesen, 
Mohr, et al., 2007).  In Brown et al.’s (2005) review of literature of stress-relapse interactions 
both prospective and retrospective studies have found positive and negative outcomes for the 
effect of stress on MS disease. Additionally, Brown et al. suggest that because people with 
MS believe there is a strong link between stress and disease activity there may be a bias in 
reporting MS symptomatology.    
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 Studies showing stress as a factor to increased disease activity are frequently based on 
subjective measures of stress. On the other hand, Mohr and team (2000) have combined 
subjective (self-rating) and objective (MRI) outcome measures in a cohort of people with 
MS. The study found that relationship conflict increased the risk for new radiological disease 
activity at eight weeks’ past stressor event. In 2010 Yamout and colleagues (Yamout, Itani, 
Hourany, Sibaii, & Yaghi, 2010) conducted a small retrospective study to examine the effect 
of stress on MS. The study compared new enhancing lesions on MRI for the period before, 
during and post war and found an increasing likelihood of clinical relapses and radiological 
disease activity during the Israeli-Lebanese war in July 2006.  Both studies were conducted 
with small cohorts and had different study designs but they do provide some of the first 
objective evidence of the effect of stress on MS disease activity.  
 Types of stressor events have been postulated as a factor in perceived stress. Severe 
stress induces high levels of cortisol release, known to have anti-inflammatory effects.  A 
number of studies in MS have examined stress frequency, severity and type of stress and 
found that moderate, chronic stress is a factor for increased risk of MS relapse, as is the 
timing of the stress event (Ackerman et al., 2002; Brown et al., 2009; Mitsonis et al., 2008; 
Mohr et al., 2000; Potagas et al., 2008; Yamout et al., 2010).  
 The study by Potagas et al. (2008) found that an increasing number of stressful life 
events contributed to MS disease. This one-year prospectively designed study followed 37 
women with MS. The group consisted of women over the age of 18 years, had a mean EDSS 
of 0.5 (range 0-3) and a confirmed diagnosis of RRMS. Participants recruited to this study 
were also required to have had at least one relapse in the previous year. The mean number of 
relapses for this cohort was 1.5 (range 1-4). During the study, none of the participants were 
treated with disease modifying therapies, as per local investigator-institution protocol, 
although they were treated with corticosteroids for acute relapses. Having confirmed MS, at 
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least one relapse in the previous year and not being treated with a disease modifying therapy 
might add to or introduce a specific bias to the type of stress. Stressful events were self-
reported in a questionnaire format collected every 4 weeks. In this group of people stressful 
events were explored by the study team to further describe episodes and define as mild or 
serious events of stress. Categories of stressful life events included family problems, 
sentimental/sexual problems, professional/financial problems, social problems, everyday 
problems and health problems or a family member or friend. 291 events were reported, 
predominantly mild events, 268:23 (mild: serious). Eighty per cent of the group experienced 
MS relapse during the one-year observation period. Of the relapsing participants, half had a 
single MS relapse and the remainder had 2-3 relapses in the course of the study.  A bias of 
this study is not treating the study group with DMT. Clinical relapse is, in practice, the time 
to review the MS disease severity and consideration of therapy efficacy or if not on therapy, 
time to commence DMT. Ongoing clinical attacks are very likely to be stressful to PwMS, 
potentially leading to over reporting of events or at the least, more frequent medical review of 
the PwMS, interruption to the PwMS’ life, and a reduced ability to carry out their personal 
and professional responsibilities.  The investigators found factors for greater risk for MS 
relapse included disease duration equal to or greater than three years (hazard ratio 2.3), 
between two and four mild stressful events before the study commencement (hazard ratio 
2.0), three, four or five stressful events during the study (p = <0.0001, hazard ratio 6.7), 
Hamilton rating scale for anxiety (HAM –A) score of 14-17 and 18-33 (hazard ratio 2.1 and 
4.4 respectively) and episode of infection (p = <0.0001, hazard ration 5.5). Furthermore, the 
number of stressful life events correlated with anxiety scores, as measured by the HAM –A. 
No stressful life events were associated with a lower HAM –A. Participants with increasing 
number of stress life events had associated increased anxiety (HAM-A) scores.  This outcome 
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was not true for severe stressful life events, with no association found with increased risk for 
relapse.   
  The Brown et al. (2009) group set out in their study to determine if it’s possible to 
identify predictors to psychological distress and fatigue in 2009.  The researchers aimed to 
longitudinally evaluate anxiety, depression and fatigue temporally. They prospectively 
studied MS stress events every 3 months for 2 years in a population of people with MS (n= 
101). Disease factors were evaluated for relationship with demographic, psychosocial and 
lifestyle factors. Stressors were classified as acute (less than six months in duration) or 
chronic (longer than 6 months in duration), MS relatedness (whether the stressful event is 
related to the person’s MS or not), and positive or negative stress using the Bedford college 
life events and difficulties schedule (LEDS). The stressors were further categorised into 
chronicity, frequency, severity, cumulative effect, MS-relatedness, valence and positive 
versus negative stress. Using univariate categorical and continuous measures for data 
analysis, this study found that the presence of life event stressors predicted increased fatigue, 
depression predicted anxiety and fatigue and psychological distress also predicted unhealthy 
behaviours (e.g. smoking, recreational drug use, no exercise and reduced relaxation).  
 The role of stress event frequency can be seen in a small prospective study by 
Mitsonis et al. (2008). Limited to female participants this project followed 26 women with 
MS for 56 weeks. The participants were seen every 4 weeks and additionally completed self-
report diaries. Stressful events were categorised as short term or long term and were 
determined for severity using the Recent Life Change Questionnaire. This study found the 
number and duration of stressful events were associated with an increased risk of relapse, 
with just one long-lasting stress event increasing the risk of relapse 3-fold. The type and 
severity of stressor were found to have no influence on relapse risk. The timing of stressors 
plays a role in the relationship between stress and MS relapse risk. Observational studies 
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have shown that the period immediately following stressful life events (independent of 
stressor severity) can hold an increased risk for clinical relapse (Ackerman et al., 2002; 
Yamout et al., 2010).  
 There are conflicting views on the effect of severe stress on relapse.  Nisipeanu and 
Korczyn (1993) and  Yamout et al. (2010) chose the well-defined stress event of living in a 
war zone to investigate risk of relapse likelihood. The earlier study prospectively followed 32 
patients with definite MS through their experience of living in Tel Aviv during the Persian 
Gulf War of 1991. The demographics of this small group were reasonably representative of 
the MS population: 18 women and 14 men with an EDSS range of 1.0-6.0, an average age of 
38 years and an average disease length of 4.7 years (range 2 to 15 years). The number of 
relapses in the previous 2 years for each person with MS was 2-5. The only treatment 
received by that group was steroids for acute relapse. During the 3-month follow up only 3 
confirmed relapses occurred in the group, which was a significant reduction compared to the 
pre-war relapse rate.  As well as having a small cohort size, a fundamental issue with this 
study is bias for reporting new neurological symptoms in the context of difficulty seeking 
medical attention during active bombing and subsequent difficulty mobilising around the city. 
It is possible that relapses were less often reported for minor relapses.   
 More recently, however, a larger study of people with MS during war time (Yamout 
et al., 2010) found a significant increase in MS disease activity, both in clinical relapses and 
by radiological measurement. This study of 216 people, who were directly affected by the 
Israeli-Lebanese war in 2006, compared relapse rate and number of new lesions before, 
during and after the war to a control group examined outside of war. This more detailed study 
reported both an increased risk for clinical relapse and new lesions on MRI during war time. 
This study has greater validity to the previous study as it had a larger study cohort, used 
objective MRI data assessments and included a control group. A likely criticism of this study 
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is that there is no measurement or discussion of the relationship between timing of the 
stressor and the relapse. Exposure to stress (emotional and physical) is a usual consequence 
of the human condition, as are relapses of MS. Adding in acute stress of living in a war zone 
it is reasonable to cogitate where correlation ends and concurrence intersect.   
Few studies have examined the relationship between stress and MS disease onset. In 
the United States of America (US) (Riise et al., 2011) a sub study of a longitudinal population 
based study, the Nurses’ Health Study (NHS I) and Nurses’ Health Study II (NHS II),  found 
severe home stress did not increase the risk for MS. This large study identified 369 (NHS l: 
77 participants and NHS ll: 292 participants) people diagnosed with probable or definite MS. 
The study asked participants every 2 years about their level of stress at work and home (as a 
generalised statement of minimal, light, moderate or severe) and about severe childhood and 
adolescent stress (sexual and physical abuse). This study found no relationship between stress 
and disease onset.  Limitations of this study include not including stress event information 
beyond physical and/or sexual childhood and/or adolescent abuse. The every-other-year 
survey did not capture any detail about stressors beyond their type, perhaps missing 
information including stress frequency, event type and timing. Lastly, the cohort is limited to 
include female nurses only, which is not wholly representative of the MS population.   
 While the evidence above could clinically support stress as a risk factor for MS 
disease this contrasts with the known HPS axis model of immune mediated cortisol release. 
Under stress the immune system will release cortisol, an anti-inflammatory hormone. Animal 
models of neurological inflammation, experimental autoimmune encephalitis (EAE), have 
shown that stress can reduce inflammation (Heesen, Gold, Huitinga, & Reul, 2007). In 
humans it is proposed that severe stress triggers cortisol release and is thereby protecting 
against inflammation while moderate or mild stress does not (Heesen, Gold, et al., 2007). In 
relation to the above studies this concept does not hold true, as both studies used populations 
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under severe stress and yet came to different conclusions. Furthermore, neither study 
incorporated analysis of cortisol levels, and so confluence of hypothesis and outcome is 
merely speculative.  
 The studies described indicate an evolving assemblage of literature for the role that 
stress plays in MS; specifically, the number, timing, type and severity of stressful events. The 
sparsity of literature outlined above demands further research to better understand the 
relationship between stress and MS activity, especially including objective study 
measurements.  
2.3 Stress Management in Multiple Sclerosis 
 There is a substantial economic burden associated with MS. In Australia this burden is 
frequently a result of loss of productivity with estimates of annual costs identified ranging 
from AUD $36,369 (for mild disability) to AUD $ 65,305 (for severe disability) (Palmer, 
Colman, O'Leary, Taylor, & Simmons, 2013). Of the literature about stress management 
strategies searched, six papers met the criteria for inclusion in this review. The most 
compelling evidence of benefit in managing stress in MS is by Mohr et al. (2012).  This 48-
week study conducted in the United States was case-controlled (n = 121) with participants 
using a routine clinical questionnaire to assess stress reduction benefit. The case group (n = 
60) received stress management therapy for 24 weeks and comparisons were made with a 
wait list control group (n =61). The stress management therapy programme involved 16 
sessions with licensed psychologists. The programme comprised CBT with additional 
individualised sessions for specific psychological and MS-specific issues.  The wait list group 
participated in a workshop some 10 months or more after enrolment. MRI, a commonly-used 
tool for assessing MS disease activity and progression was then conducted on participants 
during the therapy and at 24 weeks. A significant reduction (p=0.04, absolute risk reduction = 
22.2%) in the number of brain lesions in the treatment group was found when compared to 
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the control group at the first-time point of analysis. Unfortunately, this benefit was not 
sustained beyond the 24 weeks of stress management treatment programme. While this was a 
labour-intensive intervention it tailored the intervention to meet the needs of the individual 
participants and there was a very high intervention adherence rate and low dropout rate. The 
authors acknowledge limitations of the study, one of which being limited clinical outcome 
measures. This study has not been replicated and differs from the other studies in intervention 
type, assessment measures used and delivery type. It’s value for comparison to the current 
study is limited.  
 A prospectively-designed, randomised control trial conducted by Artemiadis et al. 
(2012) in Greece found that implementing stress management of relaxation breathing and 
PMR twice a day for 8 weeks produced a small reduction in perceived stress (p= 0.2). This 
trial of 61 participants used a range of self-rating measures (Perceived Stress Scale, Health 
Locus of Control, State-Trait Anxiety Inventory Scale, Beck Depression Inventory and 
Symptoms of MS survey) to evaluate the intervention against a waitlist group. This study 
recruited from a pool of PwMS and excluded people who were under consenting age (i.e. 18 
years), those treated with corticosteroids for acute relapse, those living in rural areas, and 
people taking psychotropic medications (e.g. antidepressants). They also excluded people 
with progressive MS. Some of the exclusion criteria are reasonable (over the age of 18 years 
is an ethical consideration, participants from rural areas is practical exclusion and excluding 
those treated with corticosteroids will reduce the risk of mood and psychiatric side effect on 
stud outcome). Excluding those treated with psychotropic therapies and progressive MS 
introduces effect bias and reduces the study generalisability. The small cohort size and lack 
of objective measurements are also criticisms of this study.  
 PMR as a stress management strategy was also used by Ghafari et al. (2009) in a 
small quasi experimental design study trial of 66 people (33 case participants and 33 control 
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participants) with MS. Similar to the study conducted by Artemiadis, the participant 
demographics excluded those who had used relaxation techniques in the 6 months prior to 
study enrolment. This group were further narrowed by excluding potential participants with 
'other acute or chronic physical disorders, severe cognitive deficits, hearing loss, vocal 
disorder or having signs of psychiatric disease' (Ghafari, 2009). Case participants were asked 
to perform this stress management strategy daily over 8 weeks while the control group had no 
intervention during the course of the project. A small selection of self-rating questionnaires 
(Individual Information Questionnaire, SF-8 Health survey and a self-reported check-list) 
were used to assess benefit. The SF-8 was repeated at 4 weeks and at 8 weeks after baseline; 
test-retest reliability was 0.89. The results of this study showed similar scores for health-
related quality of life before the study but the case and control group were significantly 
different (in favour of the intervention group) at 1-month (p=0.0001) and 2 months 
(p=0.0001) post intervention. An obvious criticism of this study is the shortage of 
intervention measurements, including objective appraisal of the intervention. Supplementing 
the SF-8 with more comprehensive mood assessment would have provided a comprehensive 
examination of the intervention’s effect.  PPMS was not represented in the study cohort.  The 
small cohort and absence of perceived stress measures reduce this study’s comparability with 
the primary outcome of the current study.  
 Stress Inoculation Training (SIT) was conducted by Foley et al. in an outpatient 
setting with MS patients (F. W. Foley et al., 1987).  Forty-one participants were assigned to 
either the SIT or usual care.  Analysis was completed on 36 participants as five failed to 
complete the pre-post-test self-reports. The participants had clinically definite MS; 85% 
females (n= 30), had an average age of 39 years, were separated or divorced (55%), and were 
unemployed (58%). This particular project differs to the other studies in that the cohort being 
studied had greater disability and active disease (as evidenced by a mean EDSS of 6, range 
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1.0-8.0, and clinical relapse confirmed at all-time points of the study – entry: 60%, post-test: 
58%, 6-month follow up: 60%). There is no clarification of MS type but the cohort 
description suggests that people with both early and late disease were included. The SIT was 
a 6-session programme based on CBT and utilised more complex psychological therapy. 
Additionally, PMR was employed in some sessions of the programme. This intervention was 
facilitated by an advanced practice psychology student, supervised by licensed clinical 
psychologists. Intervention evaluation was measured using the Beck Depression Inventory, 
the State-Trait Anxiety Inventory, the Hassles Scale and Rotter's Internal -External Locus of 
Control Scale. At analysis, the SIT group (n =20) had significant reductions in depression, 
state anxiety, hassles and improved problem-based coping compared to the control wait list 
group. Unfortunately, follow up evaluation at six months’ post programme was only able to 
be performed on half (n= 10) of the SIT group. However, the investigators report sustained 
benefit for the SIT intervention at follow up. This outcome may represent a type 1 statistical 
error because of the small followed cohort, which might have also selected only highly 
motivated participants. 
 Another prospectively designed case-control trial by Hughes et al. (2006) found 
sustained benefit from a stress management programme that was group-based, moving away 
from one-on-one sessions described in the previous interventions. This project evaluated a 
health promotion-focused support group for women with a range of chronic, largely 
physically-affecting illnesses. 
 This self-management health promotion workshop was held weekly for 6 weeks. The 
group of 63 participants were randomly assigned to either small group workshop sessions 
(n=25) or wait-list (n= 38). The six sessions addressed theory-driven topics of understanding 
stress and stress triggers, learning stress management techniques and practising and 
promoting the techniques for ongoing use, independent of the group. Multiple measures of 
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outcome held that the programme showed benefit in reducing stress. Pre-test/post-test and 3-
month evaluation of multiple self-rating measures, including the SF 36, Perceived Stress 
Scale (PSS), General Mental Health and Role Limitations. Medical Outcomes Study Short 
Form -36 (SF36), Generalised Self-Efficacy Scale, Stress Management Self Efficacy Scale, 
Social Connectedness Scale-Revised, Health Promoting Lifestyle Profile. PSS were 
significantly reduced (p=0.0001) over time in the intervention group whereas the waitlist 
group did not show significant perceived stress reduction (p=0.486). Of the SF36 
subcategories, only mental health showed a significant difference between the intervention 
and wait list cohorts (at 3 months’ post study commencement, p=<0.01). Of the remaining 
measures, social connectedness (p=<0.5) represented a measure that improved beyond the 
intervention, i.e. 3 months after the workshop. As a study whose main goal was to ameliorate 
stress and promote health it showed lasting positive improvements in social connectedness 
and self-efficacy through group workshops. Limitations of this study are the small sample 
size (of which the subpopulation of MS was small), further amplified by attrition at the final 
follow up, the use of multiple self-rating study measures (no adjustment for multiple testing) 
and lack of objective outcome measures.  
 Kolahkaj & Zargar (2015) administered an 8-week mindfulness based stress reduction 
programme to 40 women with MS in Ahvaz, Iran. The mean age for this cohort was 25 years 
in both the intervention and the wait list group. The only study measure for this study was the 
DASS21, which was measured at baseline, at the end of the 8-week programme and repeated 
8 weeks later again. The outcome was improvement of stress, anxiety and depression scores 
(p=<0.01). The limitations of this study include small cohort, lack of male participants and 
lack of objective measures. Bias is introduced in this study as potential participants were 
completed a study briefing session prior to being randomised, reducing natural attrition. The 
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effect of this method of recruiting will be including only highly motivated participants, thus 
reducing the generalisability of the outcome.  
 A recent small feasibility study explored the role of mindfulness based stress 
management (MBSM) in PwMS with considerable disability (Simpson, Mair, & Mercer, 
2017). The study included participants of any type of MS and with an EDSS of equal to or 
less than 7.0. The aim was to determine if recruitment, programme delivery, retention, 
outcome measurements and likely effect of the MBSM intervention were feasible. Of these 
objectives, all were met with varying effect size.  MBSM was delivered in up to eight group 
sessions, delivered by trained clinicians. Attendance to the sessions was considered good if 
participants attended four or more sessions; 60% of intervention participants attended this 
number of times. Content for the intervention included home practice materials on top of 
skills learned at the face to face sessions. Outcome measures were all self-rating 
questionnaires. This type of assessment is not costly and easy to administer but reduced the 
robustness of the results. The primary outcome of the study was met with a significant 
reduction in perceived levels of stress (p<0.01), measured at the completion of the face to 
face sessions but diminished to a small effect size (p=0.13) at 3 months’ post face to face 
sessions.   Secondary endpoint measure of quality of life measures scored a small effect size 
at intervention end and negligible at 3 months ‘post intervention. As a feasibility study this 
project demonstrates promise for the role of MBSM to reduce stress and improve quality of 
life. However, significant difficulties including short lasting effects and intervention 
attendance need to be addressed for the results to be demonstrated in larger studies.   Again, 
the study cohort is small, the intervention type is different to the current study (group 
sessions) and assessment measures all are self-rated. Recruitment bias for moderate or high 
disability excludes a significant portion of the MS community and further reduces eligibility 
for comparison with the current study.  
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Table 1. Summary, studies of stress management in MS  
Publication  Study 
design 
n= Intervention type Primary Outcome and 
Measurement 
P -value 




25:25 MBSR2, group sessions 
for up to 8 weeks  
Perceived Stress (PSS8)  < 0.01 




MBSR, group sessions 
for up to 8 weeks 
Perceived Stress Depression, 
Anxiety (DASS21)  
   
< 0.001 
  





and PMR, up to 8 
weeks duration 
Perceived Stress (and 









CBT4 based stress 
management, up to 16 
sessions  
 
MRI5 (new Gad lesions) < 0.02 
  
Ghafari et al. 
2009 
RCT 33:33 PMR7 over 8 weeks QoL6 (SF-8) < 0.05 
  









Perceived Stress (PSS) < 0.0001 




20:16 CBT +PMR, up to 6 
sessions 
Distress (and Depression, 
Anxiety) (Hassles Scale) 
< 0.01 
1RCT = randomized controlled trial 2MBSR = mindfulness-based stress reduction 3Dep/Anx. = depression/anxiety 
4CBT = cognitive behavioural therapy 5MRI = magnetic resonance imaging 6QoL = quality of life 
7PMR = progressive muscle relaxation 8PSS = perceived stress scale 
 
2.4 Mindfulness 
 Mindfulness is a practice based on Buddhist philosophy of non-judgemental, moment 
to moment awareness of being that is increasingly being used as a therapy in a range of 
chronic conditions, for example cancer (Bauer-Wu, 2010) and chronic pain (McCracken & 
Vowles, 2014). Mindfulness is a practice that can be used by an individual or in group 
settings.  When applied to stress management mindfulness encourages an intentional 
awareness of thought to develop a plenteous understanding of the lived experience to reduce 
intense and instantaneous reactivity to stressful events (Grossman, Niemann, Schmidt, & 
Walach, 2004).  
 Mindfulness has been much studied in well populations (Duncan & Bardacke, 2010; 
Sharma & Rush, 2014), chronically ill populations (Carlson, Speca, Patel, & Goodey, 2003; 
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Teasdale et al., 2000) and stressed populations (Grossman et al., 2004). MBSR programmes 
have evolved in the 21st century (Bauer-Wu, 2010) as wholistic approaches to health care. 
Bauer-wu (2010) suggests interventions based on MBSR continue to be implemented and 
studied as the health benefits for mindfulness are increasingly evidenced over a large range of 
illnesses and populations. MBSR and mindfulness based cognitive therapy (MBCT) studies 
have shown to change brain connectivity by functional MRI (fMRI) and functional 
connectivity MRI (fcMRI). In 2011 Kilpatrick found that after an 8-week programme of 
mindfulness meditation training, a population of healthy women had increased connectivity 
over auditory and visual pathways on fMRI. More recently, Gotink, Meijboom, Vernooij, 
Smits, and Hunink (2016) reviewed the available evidence for functional and structural 
changes in the brain after an MBSR programme of 8 weeks duration. Changes to the 
prefrontal cortex, cingulate cortex, the insula and hippocampus were reported.  
 In MS mindfulness has been scantly studied. A mindfulness of movement (Tai Chi/Qi 
Gong) programme was assessed in a small pilot study of 16 people with MS (Mills & Allen, 
2000) in the United Kingdom.  This controlled study (cases n=8, control n=8) was undertaken 
on people with SPMS and assessments on balance and MS Symptom Rating Questionnaire.  
It was demonstrated that mindfulness of movement was beneficial in coping with MS at the 
end of the intervention and 3 months after the intervention.  
Grossman et al. (2010) performed a randomised control trial of mindfulness training in 
people with MS to assess the effect on health-related quality of life, depression and fatigue. 
One hundred and fifty people with MS were randomised into case (n=76) and control groups 
(n= 74). The intervention was group based and consisted of 8 weekly sessions, a full day 
retreat and home work.  The study population were either RRMS (with no more than 2 
relapses in the previous year) or SPMS and had an EDSS of ≤6.0 and ≤1 step increase of 
EDSS in the previous year. The cohort has similar demographic makeup between case and 
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control groups and also reflected the general MS population.  Outcome was assessed with 
largely patient-reported measures, including the Profile of Health-Related Quality of Life in 
Chronic Disorders, Hamburg Quality of Life Questionnaire in Multiple Sclerosis, Centre for 
Epidemiologic Studies Depression Scale, Modified Fatigue Impact Scale, Speilberger Trait 
Anxiety Inventory, neuropsychological assessment and a post intervention questionnaire. 
Intention to treat analysis showed that mindfulness training in this cohort improved quality of 
life for at least 8 months among mild to moderately impaired patients independent of 
depression, fatigue of other psychosocial problem. While this study has shown improvement 
in depression, anxiety, fatigue and overall quality of life in MS it does not specifically 
address perceived levels of stress and so cannot be used to draw conclusions about 
mindfulness as a tool for stress management. 
 More recently an Iranian study evaluated an 8-week MBSR group course on women 
with MS (Kolahkaj & Zargar, 2015). The study used the DASS21 tool to examine depression, 
anxiety and stress before, immediately after and two months after completing the course. 
Participant numbers were low (20 in each intervention and usual care groups) and only 
included women, but were able to demonstrate a decrease in depression, anxiety and stress, 
not only between the intervention and usual care groups, but also pre-test compared to post-
test (immediately following and 8 weeks after conclusion of the course).  The course 
employed mindful breathing, watching, hearing, eating, meditation, behavioural awareness 
and body scanning over 8 weekly sessions. The usual care group were assessed at the same 
time as the intervention group and offered the course at the conclusion of the study. 
 The available literature has demonstrated that simple, self-management techniques of 
stress management can have short and long-term benefits in the MS population, on reducing 
perceived stress, quality of life and other psychological measures of wellness.  Mindfulness 
interventions are well-established as an effective tool to reduce stress in non-MS populations. 
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Prospective, controlled and randomised studies of mindfulness interventions in the MS 


















    METHODOLOGY 
3.0  Introduction   
 This chapter describes the methodological approach and procedures used to conduct 
the study.  The design, sample and data collection procedures are described.  The instruments 
used are presented and the reliability and validity of the instruments are discussed. This 
chapter also includes details of data analysis and the ethical considerations concerned with 
undertaking this study.  
3.1 Research Design 
 This controlled, prospective study combined quantitative and qualitative research 
approaches to examine the research questions. Over the course of the project participants 
were asked to evaluate their levels of stress, their assessment of how they managed their 
stress and their assessment of how the intervention affected their levels of stress. Quantitative 
data was collected using repeated measures, at baseline and at 1 month, 3 months and 6 
months intervals, and included salivary cortisol levels and levels of perceived stress. 
Perceived stress was assessed using the DASS21, stress Visual Analogue Scale (sVAS) and 
MusiQoL. All three questionnaires contain a subjective rating of perceived stress levels. 
Thematic content was performed on responses derived from participants’ diary completion. 
The diary was primarily used to gather information on intervention adherence; diary 
completion beyond adherence was optional to study participants (see Appendix 1).  This 
integrative approach seeks to examine the human, lived experience; enabling an exploration 
of the complex human physiological and emotional response to stress by asking participants 
to describe their feelings and responses to stress and stress management as well as using a 
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standardised evaluation of their perceived levels of stress.  Using mixed method in research 
can answer research questions from a number of perspectives, reduce the gaps in data 
collected and reduce the likelihood of assumptions being made by the researcher during data 
interpretation (Bulsara, 2015). A mixed method approach is therefore relevant for this study.  
This approach, also known as triangulation research, has gained popularity over traditional 
single approach models in social sciences research.  In early social sciences research this 
approach was frequently cited by Campbell and Fiske in the 1950s (Jick, 1979) and continues 
to be a popular approach to social science and nursing research. In this study, the data was 
derived concurrently.  
3.2 Setting 
 Participants were recruited for the study from the MS clinic within a tertiary hospital 
in Newcastle, Australia. This MS service provides care to over 800 people with MS. The 
service includes undertaking neurological assessment for suspected MS as well as providing 
advice and care for people with newly diagnosed and long-standing MS. 
 The setting is a large outpatient department that houses multiple medical clinics every 
day of the working week. The consulting rooms have a mostly clinical aesthetic, with an 
examination bed and chairs, wall oxygen and suctioning equipment and strong lighting. Each 
consulting room is set up with a computer and a phone. Outside the cluster of consulting 
rooms is the focal hub of administrative and nursing support – the noise from this area is 
rarely heard from inside the nearby consulting rooms. The study participants were seen in 
various consulting rooms within this area. There was very little variation between the rooms.  
Occasionally participants were seen in the Neurology Clinical Support Unit or their home due 
to lack of space in the outpatient department or convenience for the study participant and/or 
study investigator (i.e. participant limitation of time to be seen and unable to secure a room 
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the outpatient department). During the course of the study it was identified that some 
participants were unable to be recruited due to living a considerable distance from the 
hospital and not being able or motivated to attend for the weekly intervention sessions. These 
study participants were offered home sessions, which were duly coordinated and conducted 
by the study investigator.  
During the study visits the participants were seen one on one. Occasionally a 
participant was accompanied by a friend or relative. Support people were encouraged to wait 
in the waiting area for the duration of the visit. Participants attending the hospital for the 
study were offered car parking vouchers. This was done to avoid penalising participants for 
the extra time or making participation in research prohibitive. 
3.3 Sample Population  
 The participants recruited to this study were people with MS (PwMS) between the 
ages of 18 and 65 residing in the Hunter New England region of New South Wales and 
utilising the MS clinic at the John Hunter Hospital for their care. The sample group was made 
up of both male and female participants, although female participants made up the greater 
proportion of study participants, reflecting of the MS female: male ratio of 3 females to each 
male (Kalincik et al., 2013).  The study included a wide range of social backgrounds: people 
employed, not employed, on home duties, retired or on disability pensions. Participants were 
in relationships (married, de facto or not living together), single or divorces.  Potential 
participants identified and offered information about the study in the clinic over the 
recruitment period of 18 months.  
3.3.1 Inclusion/ Exclusion Criteria 
 The age of the participants was limited to being between 18 and 65 years of age (to 
reduce risk of age-related cognition issues) and all participants had a diagnosis of MS. Length 
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of disease since diagnosis was noted but not used for exclusion to participation. Previous 
exposure to or use of meditation and/or PMR was not considered an exclusion recruitment. 
Exclusion criteria included: - 
1. People with significant medical and/or psychological illness,  
2. MS relapse with or without steroid treatment within one month of enrolment in the 
study,  
3. Cognitive dysfunction (determined by inability to complete the Audio Recorded 
Cognitive Screen),  
4. Inability to read or write English,  
5. Severe muscular spasms, and  
6. Participants with recent treated relapse.  
Recent treated relapse was excluded because the standard treatment for relapses consists of 
intravenous high dose steroid; apart from affecting the objective outcome measure, a side 
effect of this therapy is altered mental state. The rationale for excluding untreated relapse was 
to avoid the significant emotional distress or adjustment as a direct result of the relapse. In 
addition, clinical stability during the assessment period is required to exclude potential bias 
from improvement after relapse. Cognitive dysfunction and inability to write or read in 
English would compromise the person’s ability to complete the screening and follow up 
assessments, and follow the instructions while performing meditation and PMR exercises. 
People with severe muscular spasms were excluded from the study because this would 
prevent participants from performing the PMR; an intervention that required participants to 






 Participants were recruited through the neurology outpatient department during the 
period January 2015 to July 2016 and were approached to consider the study by one of the 
clinic neurologists, neuro-immunology fellow or the clinical trial coordinator. The clinic 
appointment list was examined by the study investigator for potential participants and the 
clinician involved was provided with a study participant information and consent form 
(PICF) to give to the potential participant. One of the team members introduced the study to 
potential participants during routine consultations. (see Appendix 2). Any questions from 
potential participants were answered by one of the team or the study investigator. If potential 
study participants were happy to proceed to consent they gave written consent in the presence 
of the neurologist. Their contact details were then forwarded to the study investigator. At this 
point the study participant was randomised to intervention (case) or wait list (control) group 
and initial assessments were either collected or scheduled for collection.  
3.4 Informed Consent Process 
 Ethical approval for this study was obtained from Hunter New England Local Health 
District Human Research Ethics Committee (approval number 14/06/18/4.02) and the 
Murdoch University Human Research Ethics committee (approval number 2014/118) 
Informed consent was obtained by either the neurologist or MS clinical trial coordinator. 
Potential participants were identified prior to or during routine outpatient clinics and offered 
verbal and written information about the study. Once the neurologist or clinical trial 
coordinator were confident that all questions regarding the study were answered and the 
participant had agreed to participate, both the neurologist and the participant would sign and 
date the consent form. The participant’s details were then forwarded to the researcher to enrol 




 To maximise study robustness a free online randomisation tool, Research 
Randomizer, was used to assign consented participants to either the intervention (case) group 
or the wait list (control) group.  This tool was developed by the Social Psychology Network 
(Urbaniak & Plous, 2013) and uses a pseudo-random number generator. The programme 
provided a series of number ‘1’s and ‘2’s for 100 participants. Each ‘1’ indicated a case 
participant and a ‘2’ indicated a waitlist participant. An assignation of case or wait list was 
allocated upon receiving written consent completion. 
3.6 Intervention (Case Information Package) 
 The PI met with case participants weekly for up to four weeks. At the sessions, which 
lasted on average one hour, participants were taught mindfulness, meditation and progressive 
muscle relaxation. At the first visit case participants were given a study package; this 
contained an educational brochure on stress in MS entitled Taming Stress in MS: Staying 
Well (F. Foley, 2012), a meditation compact disc (CD) with a twenty minutes guided 
meditation and a ten-minutes guided PMR. The meditation was designed and recorded by a 
local psychologist with design input from the study investigator. The pretext and text for the 
guided meditation was designed by the psychologist and the study investigator to provide a 
general introduction to meditation, with an emphasis on mindfulness. This was done to assist 
those participants who have never had or have only had little experience with guided (or 
otherwise) meditation. The PMR text was taken from Taming Stress in Multiple Sclerosis: 
Staying Well (Foley, 2012), recorded and used with permission from the author, Fred Foley, 
for this project (see Appendix 3, ffoley1@oal.com).  
Mindfulness exercises included diaphragmatic breathing and body scanning, key 
meditation skill development of focussing on being present in the now, and finally reflecting 
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on individual stressful scenarios and applying mindfulness principles for future exposure to 
said stressor exposure. This reflection consisted of recognising the emotion attached to the 
stressor (e.g. fear or sadness), exploration of the feeling - assignation and description of how 
that feels in the body (e.g. headache or tight muscles, hot or jelly-like, rating out of 10), 
acceptance or allowing of the emotion, practising non-identification or acceptance of those 
feelings. In this way, the participant learned to respond differently and feel differently about 
situations that have previously caused increased stress. Participants were encouraged to 
perform mindfulness, meditation and PMR on a daily basis for 20 minutes per session and to 
record their exercise completion and reflection in a diary. Follow up assessment was 
scheduled for 6 month’s post programme. 
3.7 Screening  
 Screening assessments were applied once the consent form was signed and the 
participant randomised. The Audio Recorded Cognition Screen (ARCS) was used to 
determine if the participant had a significant level of cognitive impairment, which would 
preclude her/him from inclusion. If at the time of consent or enrolment an ARCS had recently 
been performed (within 12 months), for example, as part of routine clinic care, then that 
assessment would be used for the study screening measure.  The EDSS was used to describe 
the population, in order to define the level of physical disability in the study population.  
3.7.1 Audio Recorded Cognition Screen (ARCS) 
 For screening potential participant’s routine cognitive assessment was used to identify 
people with limitations in cognition. Severe cognitive dysfunction was exclusion for 
participation in the study. Cognitive screening is performed routinely in clinical practice and 
if performed within 12 months of study entry the score was sourced from the participant’s 
health records to minimise the burden on patients of repetitive screening and to reduce 
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learned effect of this assessment. The Audio Recorded Cognition Screen (ARCS) is a short 
screening tool to assess cognition domains including executive function, memory, visual 
spatial construction and language. The ARCS is administered by audio disc. Validation of the 
ARCS tool in MS was undertaken in 2010 and it was found to have better sensitivity (86%) 
compared to an equivalent tool, the Paced Auditory Serial Addition Test (PASAT) (68%) at 
an equal specificity (71%) (Lechner-Scott et al., 2010).  
3.7.2 Expanded Disability Severity Score (EDSS) 
 The EDSS was used to describe the sample population and to describe disease 
stability or progression over the course of the study. The EDSS is an ordinal clinical rating 
scale that is rated according to seven neurological functions (visual, cerebral, pyramidal, 
cerebellar, brainstem, sensory, bowel and bladder, and ambulation) affected in MS (Kurtzke, 
1983). It is used as a quantitative method of assessing disability. An EDSS of 0.0 indicates a 
normal neurological examination, 1.0 indicates signs but no disability, after 4.0 indicates 
walking distance is limited to 500m, at 5.5 a walking aid is likely to be necessary from some 
to most of the time, and from 7.5 a wheelchair is required.   Disease stability in the EDSS is 
an improvement or no change in score over 6 months whereas commonly progression is 
considered a sustained increase of 1.0 points or more over 6 months (Healy, Engler, Glanz, 
Musallam, & Chitnis, 2013). EDSS is an examination routinely undertaken with MS patients 
and has previously been reported in the literature as being a reliable and valid measure of 
impairment and disability (Sharrack, Hughes, Soudain, & Dunn, 1999).  For the purposes of 
this study the EDSS was undertaken at baseline by a qualified assessor (all assessors were 
certified with Neurostatus certification (Kappos, 2016).  
 
3.8 Data Collection 
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 Demographic information including date of birth, sex, MS classification (RRMS, 
SPMS or PPMS), date of diagnosis, date and score of most recent neurological assessment 
(EDSS), current employment status, current relationship status, current medical 
comorbidities, currently prescribed medications, historical or current diagnosis or depression, 
anxiety or stress by doctor, psychologist or psychiatrist, historical or current prescription to 
treat depression, anxiety or stress was collected. The baseline survey also collected 
information about at-the-time methods of managing stress.  
Follow up visits were performed at one month (F1) and six months (F2). Follow up 
assessments included relapse details: if a relapse or worsening of MS occurred since baseline 
or last study visit, diagnosis of new or change in medical comorbidities, including depression, 
anxiety or stress, since baseline or last study visit, new prescribed medications, including 
antidepressants, anti-anxiety agents or anti-stress agents since baseline or last study visit, any 
medication adverse effects since baseline or last study visit. Additional information collected 
included change in relationship status since baseline or last study visit, change in employment 
status since baseline or last study visit, number of days meditation was performed out of last 
7 days (for intervention or case participants), number of days per week on average meditation 
was performed since baseline or last study visit (for intervention or case participants), number 
of days PMR was performed out of last 7 days (for intervention or case participants) and 
number of days per week on average PMR was performed since baseline or last study visit 
(for intervention or case participants). A review of frequency of performing meditation and/or 
PMR the required five out of seven days (on average) per week since baseline or last study 
visit for intervention or case participants. At-the-time methods of managing stress were 
performed, as was a comparison of baseline and follow up stress component of DASS21, 
including participant’s perceived reason/s for change or non-change of result (for intervention 




 Intervention or case participants were provided with a weekly diary to indicate when 
they performed meditation and/or PMR. The purpose of the diary was to measure adherence 
to the intervention and dose effect of performing meditation and/or PMR. Participants were 
also offered space on the diary to complete a reflection of their experience of performing the 
stress management strategies and their perceived stress exposures. This last purpose of the 
diary was not compulsory for participants to complete but rather contributed to the 
mindfulness exercises undertaken in weeks one to four. The stress visual analogue scale 
(VAS) was included on the diary documentation. This was to capture in real time overall 
level of perceived stress, week to week. 
3.10 Instruments  
 There were four main assessment tools used in the MindS study. They were salivary 
cortisol level, Depression, Anxiety and Stress Severity short scale (DASS21), Multiple 
Sclerosis International Quality of Life questionnaire (MusiQoL) and sVAS. The salivary 
cortisol level, DASS21 and MusiQoL were performed at baseline and one month after 
baseline. The DASS21 and MusiQoL were repeated additionally at six months post baseline. 
VAS was completed weekly by participants and formed part of the diary.   
3.10.1 The Depression, Anxiety and Stress Severity Scale (DASS21) 
The DASS21 is a quantitative self-report measure of distress which includes items on 
depression, anxiety and stress. The scale is a Likert scale. While the DASS is available in a 
42-item scale, the short form was used in this study as the two scales are comparative 
(Antony, Bieling, Cox, Enns, & Swinson, 1998) and the shorter version is less burden to 
complete by participants. The DASS 21 is a set of 21 questions asking the participant to rate 
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their level of stress, anxiety and depression as they have experienced it over the previous 7 
days. 
The DASS21 has reported good psychometric properties in several patient 
populations including those with neurological conditions.  Consistency and reliability of the 
scale ranged from 0.93-0.94 (Henry & Crawford, 2005) as measured by Cronbach’s alpha 
coefficient.  In addition, the instrument is considered an appropriate instrument regarding its 
brevity, reliability and previously reported sound structure linear self-rating scale where 0 is 
the lowest level of perceived stress and 10 is the worse stress perceivable (Henry & 
Crawford, 2005). The DASS21 was performed at baseline and at F1 and F2. 
3.10.2 Visual Analogue Scale (VAS) 
The Visual Analogue Scale (VAS) is a self-rating, validated stress measurement scale 
(Lesage, Berjot, & Deschamps, 2012). This tool was used to assess the participant’s 
perceived level of stress, week to week, over the course of the project. This scale is a linear 
self-rating scale where 0 is the lowest level of perceived stress and 10 is the worse stress 
perceivable. 
3.10.3 Multiple Sclerosis International Quality of Life (MusiQoL) 
The MusiQoL is multidimensional tool asking respondents to rate 31 items related to 
their ability to complete and participate in activities of daily living, psychological wellbeing, 
MS symptoms, relationships with friends and family, sentimental and sexual life, coping, 
rejection and relationship with the health care system. This scale is also a Likert 
psychometric scale that required respondents to rate their responses on an agree-disagree 
scale for a series of statements (Schneider, 2013). Responses are scored ‘never/not at all’, 
‘rarely/a little’, ‘sometimes/somewhat’, ‘often/a lot’, and ‘always/very much’.  The 
questionnaire takes about 10 minutes to complete. Results of the MusiQoL are linear and rate 
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from 0-100; the higher the score the better the quality of life of the respondent completing the 
questionnaire.  
The MusiQoL is a validated tool to measure quality of life specific to people with MS 
and has previously been reported to have sound psychometric properties (Simeoni, 2008). 
This international study, including a large number of PwMS patients (n=1992) conducted by 
the Simeoni group (2008) found internal consistency was satisfactory for all dimensions with 
Cronbach’s alpha coefficients ranging from 0.68 to 0.92 MusiQoL was assessed for this study 
at baseline and at F1 and F2.  
3.11 Salivary Cortisol 
 Salivary cortisol is a useful tool to objectively measure a physiological response to 
stress and stress changes (Matousek, Dobkin, & Pruessner, 2010). Using salivary cortisol was 
chosen as a straightforward and reasonably inexpensive method of collecting the expected 
1200 samples required. The Salivette kit contained a ‘bullet’ shaped cotton gauze in a plastic 
collection tube. Due to their robust stability, the 3 samples for each collection point could be 
stored in the refrigerator after collection and delivered to the pathology agent within a week 
of collection.  Cortisol levels can be affected by circadian rhythm, diet (especially caffeine 
and acidic products), stress and exercise. Salivary cortisol testing by Salivette kit occurred at 
baseline and again at week four for both interventional (or case) group and usual care (or 
waitlist) group. To incorporate the circadian effect three samples were collected at each 
assessment: 0800hrs, 1400hrs and 2000hrs. Participants were asked to refrain from eating, 
drinking or taking medication for up to 45 minutes before collecting the sample, as well as 
avoiding extreme exercise for up to 30 minutes before collecting the sample. Immediately 
prior to sample collection participant were asked to rinse their mouth out with water and 
gently chew the cotton bullet for one minute. Finally, they would return the cotton bullet to 
the Salivette tube and store in the refrigerator before delivering to a Pathology North 
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Laboratory within a few days.  Normal reference ranges for each test are as follows: 0600 to 
0800hrs- 5.5 to 28.9 nm/L, 1800 to 2000hrs – 1.1 to11.6 nm/L and midnight - <7.0 nm/L.  
3.12 Data Analysis 
 This study relied largely on quantitative analysis but also included rudimentary 
qualitative examination of the research questions, using thematic content analysis. Some 
observational outcomes are also documented. Salivary cortisol levels were compared on both 
groups at weeks one and four. Comparison of DASS21, MusiQoL and VAS provided 
subjective analysis. The DASS21 responses stratified low to high stress for pre-and post-test 
analysis and the data analysed using multifactorial logistic regression to measure the 
effectiveness of the intervention.  
The demographic information was analysed using descriptive analysis. In addition, 
analysis of the written responses to the survey data collected between case and wait list 
groups about their reflection on their management of stress were compared qualitatively. 
Qualitative data from the open-ended question item was grouped by thematic coding (Gibbs, 
2007). Comparison was drawn between perceived levels of stress, ability to recognise 
increased stress levels, current methods of stress management and perceived effectiveness of 
these employed techniques for both wait lists and cases at baseline and at each of the follow 
up time points. This was correlated with stress scores of the DASS21. 
 Disease and demographic information were collected at baseline and at the follow up 
visits. Changes in disease or social/occupational status might influence levels of stress.  
Participants who scored high on the DASS21 were referred for further assessment and 
management but remained in the study if they so wished. 
 
3.13 Ethical Considerations 
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  A number of ethical considerations arose during the study design and 
implementation. The study gained approval through the Hunter New England Local Health 
District Human Research Ethics and Governance Committee and the Murdoch University 
Ethics Committee. Both committees had standard, but conflicting, positions about 
recruitment for studies where the primary investigator was the only clinician for usual care. 
As a result, recruitment and consent was completed by the neurologist or clinical trials 
coordinator.  
 Another ethical consideration was identifying participants with significant depression, 
anxiety and/or stress issues in the context of duty of care. More specifically being able to 
identify when participants should be referred for further assessment and management. The 
DASS21 has the ability to screen for depression, anxiety and stress but is not recommended 
for making a diagnosis independent of clinical assessment by psychologist/psychiatrist or 
mental health nurse specialist (Lovibond & Lovibond, 1995).  
 Referrals for further assessment and management were made on the basis of DASS21 
scores and purposeful engagement of the participant, both by direct discussion about altered 
mood and non-direct observation. This assessment encompassed information historically 
learned or observed about the participant, derived from the existing relationship (and history) 
between the nurse and participant, previous therapeutic engagement, information from the 
treating neurologist and eliciting the participant’s psychosocial wellbeing throughout the 
course of the study. Participants with higher DASS21 scores with or without other evidence 
for altered mood or coping were offered referral for more specialised support. These 





 This chapter has outlined the MindS study design and defined methods used for study 
recruitment, consent, randomisation, data collection and analysis. It demonstrated the reasons 
for using the tools chosen, those being salivary cortisol level as objective measure as well as 
a trio of participant subjective assessments. Finally, ethical implications of research involving 
people in dependent relationships and duty of care were defined and explored. The following 




















4.1 Introduction  
This chapter describes the demographics of the participant group, provides 
quantitative results and explores the qualitative subject matter. This evaluation of results will 
focus on baseline responses comparative to F1 and F2. At F1 82% of surveys (questionnaire, 
diary, sVAS, DASS21 and MusiQoL) were available for analysis and 49% of complete 
cortisol samples (n=6 samples) were available for analysis. At F2 42% of surveys 
(questionnaire, diary, sVAS, DASS21 and MusiQoL) were completed. As a result of 
intervention adherence and significant outlier results the data was re-analysed using the 
median scores instead of mean scores.  
This chapter will describe participant group demographics (total number, total number 
female participants, total number male participants, MS type (RRMS, SPMS or PPMS), MS 
duration average and most recent EDSS. Employment and relationship state at baseline and 
follow up is provided. History of depression, anxiety and/or stress and medication treatment 
for these states at baseline and one month follow up are provided.  
Means of the intervention groups were compared across timepoints using the general 
linear model repeated measures analysis of variance. An alpha-level of 0.05 was used as the 
significance threshold. Post hoc (observed) power indicated that this sample size had less 
than 50% to detect the mean differences observed in this study.  
4.2 Demographics 
116 PwMS were offered written and verbal information and one person failed the 
screening process due to current severe psychological illness. From the group of PwMS 
offered study participation 103 people were recruited.  Of this group, two participants 
withdrew consent before randomisation (both due to change in their employment and were 
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not able to attend the hospital for the one on one sessions) and one was excluded due to 
significant, psychological illness. This participant was referred to his general practitioner for 
management. The remaining recruits were randomly placed into either the intervention group 
(n=50) or the wait list group (n=50).   
 
 
Figure 1 Flowchart of participants  
Eighty-six per cent of participants were female and 14% male. At baseline 69% were 
married (n=50) or in de facto (n=19) relationships. 31% reported their relationship status as 
single. At completion of the study 68% remained in married or de facto relationships and 
32% were single. The majority of participants experienced not change in their relationship 
status over the course of the study.  
Eighty percent of participants were on MS therapy (see table 3). 78% of cases and 72% 
of waitlist group were diagnosed with and treated for comorbidities, including disorders 
affecting psychological and other neurological health (e.g. migraine). 22% of the study cohort 
was also diagnosed with other autoimmune disorders (5 cases and 6 controls; Crohn’s disease, 
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diabetes mellitus, Graves’ disease, Sjogren’s disease). This cohort is representative of the wider 
population. In particular, age and EDSS are a good representation of the clinical group affected 
by MS.  
Table 2. Gender and MS disease demographics of study cohort. 
Cohort demographics  Intervention group Waitlist group 
Number, n (%) 50 (50)  50 (50) 
Female, n (%) 44 (88) 42 (84) 
Male, n (%) 6 (12) 8 (16) 
Median age in years (range) 44 years (22 to 67 years) 43 (19 to 72 years) 
MS type- RRMS, n (%) 46 (92) 44 
MS type- SPMS, n (%) 4 (8) 4 
MS type – PPMS, n (%) 0 (0) 2 
MS duration average in years (range) 9.8 years (1 to 35 years)  9.0 years (1 to 37 years) 
EDSS median (range) 2.6 (0.0 to 6.5) 2.7 (0.0 to 6.5) 
   
 
Table 3.  MS therapy use in study cohort at baseline 
MS therapy n (%)   n (%) 
Case total not on Tx. 12 (24)  Wait list total not on Tx. 8 (16) 
Case total on Tx. 38 (76)  Wait list total on Tx. 42 (84) 
Avonex 2 (4)  Avonex 0 (0) 
Copaxone 3 (6)  Copaxone 2 (4) 
Gilenya 19 (38)  Gilenya 14 (28) 
Lemtrada 0 (0)  Lemtrada 5 (10) 
Plegridy 1 (2)  Plegridy 3 (6) 
Rebif 0 (0)  Rebif 1 (2) 
Tecfidera 6 (12)  Tecfidera 8 (16) 
Tysabri 7 (14)  Tysabri 9 (18) 
Tx. = Treatment 
4.2.1 Employment  
Of the 100 participants 64% were engaged in casual, part-time or full-time 
employment. 26% were drawing a pension (2 aged pension and 24 disability support 
pension). 10% of the cohort were either unemployed or looking for work (n=2), unemployed 
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and not actively looking for work (n=1), on home duties (n=4) or retired (n=3). At follow up 
8% of participants reported a change in their employment; 3 participants previously 
employed became unemployed (1 of these participants ceased employment and commenced a 
disability pension), 3 participants remained working but in different roles and 2 participants 
reduced hours due to MS. 
Table 4. Employment at baseline 
Employment Intervention group, n (%) Waitlist group^, n (%) 
Full time employment 17 (34) 14 (28) 
Part time employment 17 (34) 13 (26) 
Casual employment 2 (4) 1 (2) 
Disability pension 10 (20) 14 (28) 
Aged pension 2 (4) 2 (4) 
Unemployed 1 (2) 2 (4) 
Not working, not actively looking for work 1 (2) 3 (6) 
^ 1 participant did not report employment status 
4.2.2 MS Relapse during the Study and Referral for Management of Significant Anxiety, 
Depression and/or Stress  
During the intervention period 9% (n=9) of people experienced relapse of their MS. 8 
of these relapses were confirmed by neurological assessment and 7 people were treated with a 
course of intravenous methylprednisolone (1gram daily for 3 days). The remainder of the 
study participants remained relapse free. As demonstrated in table 5, 54% (n=54) of overall 
participants were being treated for anxiety, depression and/or stress with pharmacological 
agents. At follow up 62% (n=62) were taking pharmacological agents for treating anxiety, 
depression and/or anxiety; one participants had ceased an antidepressant, two participants had 
increased their dose of antidepressant and one participant changed antidepressant type. 
Information about participation in formal psychological treatment, e.g. CBT, was not 
collected. One study participant was entered into the study but at the baseline visit reported 
significant depressive and anxiety symptoms. This person was referred back to their general 
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practitioner and psychologist for ongoing management and excluded from participating in the 
study. Consideration was given to continuing the participant in the study as per the study 
protocol for managing participants with existing or newly presenting depression, anxiety or 
severe stress but after discussion with the participant he was withdrawn from the study.  
4.2.3 Depression, Anxiety or Stress History, including pharmacological management 
Of the total 100 participants 52% (n=52) had a history of depression, anxiety or stress. 
20% (n=10) and 16% (n=8) of intervention and wait list groups respectively had a diagnosis 
of depression, anxiety of stress prior to the onset of MS. 40% (n=20) and 28% (n=14) of 
intervention and waitlist groups respectively were diagnosed with depression, anxiety and/or 
stress after MS onset. Of this group 9% (n=6) had anxiety only, 77% (n=47) had depression 
only, 12% (n=7) had anxiety and depression and 2% (n=1) had depression and high levels of 
stress (diagnosed by the participant’s general practitioner). 42 of the 52 participants (i.e. 
81%) had either recently taken or were currently taking prescribed medication for 
management of anxiety, depression and/or stress. Table 5 outlines the current prophylactic 
medication used in this cohort to manage depression, anxiety and stress. 
 
 
Figure 2. Number of new depression, anxiety and/ or stress diagnoses, by group. 
 
 




















New Diagnoses of Depression, Anxiety and/or 
Stress
Intervention group Waitlist group
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Medication Intervention group treated, n= Waitlist group treated, n= 
Selective serotonin reuptake inhibitors   
Sertraline (Zoloft) 3 2 
Citalopram (Cipramil)  0 2 
Escitalopram (Lexapro) 9 4 
Fluoxetine (Lovan, Prozac) 3 4 
Desvenlafaxine (Pristiq) 2 3 
   
Serotonin and noradrenaline reuptake inhibitors   
Duloxetine (Cymbalta)       2       1 
Venlafaxine (Effexor) 1 1 
   
Benzodiazepines   
Diazepam (Valium) 1* 1 
   
Tricyclic antidepressants   
Amitriptyline (Endep) 3# 0 
Total n PwMS on DAS treatment  24 18 
* diazepam used in combination with duloxetine in 1 participant  
# amitriptyline used in combination with escitalopram in 2 participants  
 
4.2.4 Methods of Coping with Increased Perceived Stress 
Participants were asked to list the activities they engaged in to manage or alleviate 
their stress. This information was collected using a 17-item list or activities, including an 
open item for them to list activities they participant in that weren’t included in the provided 
list. Participants were able to tick as many items as they wanted but not asked to rate these 
activities for stress management success. This information was collected at baseline, 1 month 
and 6 months. Table 6,7 and 8 outline the strategies employed by participants to manage 









Activity to manage stress at baseline Number of PwMS who 
used this strategy 
(cases) 
Number of PwMS who 
used this strategy 
(wait lists) 
Exercise     28     24 
Medication  13 10 
Drinking alcohol 11 12 
Smoking tobacco 7 7 
Using illegal drugs 3 2 
Regular meditation 8 7 
Using mindfulness 4 9 
Cognitive Behavioural Therapy (CBT) 2 3 
Talking to a psychologist 7 8 
Talking to their family 30 26 
Talking to their general practitioner (GP) 14 9 
Talking to their MS team 10 4 
Shopping 12 9 
Spending time with family and/or friends 28 20 
Deliberately avoiding the stressor 21 25 
Doing nothing at all 7 7 
Other (detail) 19 14 
  Crying  
  Eating   
  Getting angry with people 
  Avoid social events  
  Self-harm 
  Gambling 
  Yell 
  Internalise 
  Try to stay busy 
  Lying down or sleeping  
  Walking the dog  
  Playing with cat 
  Doing puzzles 
  Gardening   
  Clean house  
  Fishing  
  Going to the beach 
  Reading  
  Watching movies or television  
  Drinking tea/ coffee  
  Cooking/ Baking  
  Listening to music 
  Using the computer/iPad games/video games 
  Making candles 
  Scrapbooking 
  Colouring in 
  Knitting/Crocheting  
  Journaling  
  Genealogy  
  Prayer/bible study  
  Driving  












































































Activity to manage stress at F1 Number of PwMS who 
used this strategy  
(cases) 
Number of PwMS who 
used this strategy  
(wait lists) 
Exercise     21      23 
Medication  15 8 
Drinking alcohol 5 4 
Smoking tobacco 2 6 
Using illegal drugs 11 1 
Regular meditation 16 9 
Using mindfulness 12 9 
Cognitive Behavioural Therapy (CBT) 1 2 
Talking to a psychologist 4 6 
Talking to their family 20 19 
Talking to their general practitioner (GP) 6 6 
Talking to their MS team 8 6 
Shopping 6 14 
Spending time with family and/or friends 23 18 
Deliberately avoiding the stressor 16 15 
Doing nothing at all 1 7 
Other (detail) 8 4 
     Try to stay busy 
     Lying down or sleeping  
     Walking the dog  
     Bee keeping 
     Doing puzzles 
     Gardening   
     Reading  
     Watching movies or television  
     Cooking/ Baking  
     Listening to music   
     Using essential oils 
     Colouring in 
     Knitting Crocheting  
     Remedial massage 
     Renovating caravan 









































Table 8. F2: strategies employed to manage stress 
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Activity to manage stress at 6 months Number of PwMS who 
used this strategy  
(cases) 
Number of PwMS who 
used this strategy 
 (wait lists) 
Exercise      21      23 
Medication  7 4 
Drinking alcohol 6 5 
Smoking tobacco 1 6 
Using illegal drugs 2 1 
Regular meditation 15 8 
Using mindfulness 12 6 
Cognitive Behavioural Therapy (CBT) - 3 
Talking to a psychologist 1 1 
Talking to their family 23 22 
Talking to their general practitioner (GP) 7 6 
Talking to their MS team 3 2 
Shopping 5 5 
Spending time with family and/or friends 16 18 
Deliberately avoiding the stressor 13 13 
Doing nothing at all 2 6 
Other (detail) - - 
     Try to stay busy 
     Lying down or sleeping  
     Walking the dog  
     Bee keeping 
     Doing puzzles 
     Gardening   
     Reading  
     Watching movies or television  
     Cooking/ Baking  





















     Prayer - 1 
Total strategies: total no. respondents 141:42 133:38 
 
4.2.5 Level of perceived stress as measured by stress visual acuity scale 
Perceived stress was measured by the sVAS, which is a linear self-rating scale where 
0 is the lowest level of perceived stress and 10 is the worse stress perceivable. The baseline 
mean level of stress for the case cohort is 4.4 out of 10 (medium level of stress) and dropped 
to 3.8 out of 10 at follow up. The mean sVAS for wait list cohort was 3.7 out of 10 at baseline 
and 4.2 out of 10 at follow up. The result between groups, from baseline to F1 is p=0.8. AS 
demonstrated by the p value in table 10 F2 change is not significant. 
 
 
Table 9. Perceived Stress (sVAS) between subjects mean, baseline to F1. 
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Intervention 1 4.4 0.6 3.3 5.6 0.044 p=0.8 
 2 3.8 0.6 2.6 4.9   
No 
Intervention 1 3.7 0.5 2.8 4.6   
 2 4.2 0.5 3.2 5.1   
 
Table 10. Perceived Stress (sVAS) between subjects mean, baseline to F2. 











Bound   
Intervention 1 4.9 0.9 3.1 6.7 0.003 p=0.3 
 2 2.9 0.7 1.5 4.3   
No 
Intervention 1 4.2 0.6 2.9 5.5   
 2 3.7 0.5 2.7 4.7   
 
4.2.6 Level of perceived stress as measured by stress component of DASS21 
The DASS21 is a validated 21-item self-rating tool for measuring depression, anxiety 
and stress. Participants are asked to convey the presence of depression, anxiety and stress 
symptoms over the past week. Each item is scored from 0 (did not apply to me at all over the 
past week) to 3 (applied to me very much or most of the time over the past week). Of the 
aggregated score 0-14 indicates a normal level of stress, 16-18 is mild stress, 20-24 is 
moderate stress, 26-32 is severe stress and 34-40 is extremely severe stress. The mean score 
for the case cohort at baseline was 14.2 (p = 0.9, 95% CI [10.3, 18.1] and 12.9 at F1 follow 
up, (p = 0.9, 95% CI [9.1, 16.7], and 11.9 at 6-month follow up (p=0.3, 95% CI [7.4, 16.2] 
(see table 11). The mean score for the wait list cohort was 14.3 (95% CI [11.1, 17.5] at 
baseline and 13.1 (95% CI [10.0, 16.2] at F1 (see table 11) and 10.3 at the F2 (95% CI [7.5, 
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13.1] (see table 12). Again, there was no significant difference between groups, from baseline 
F1. 
In stratifying the responses from normal to extremely severe stress, 50% of the overall 
study cohort scored ‘normal’ stress at baseline and 53% at follow up; 16% of the overall 
study cohort scored ‘mild’ stress at baseline and 4% at follow up; 9% of the overall study 
cohort scored ‘moderate’ stress at baseline and 18% at follow up; 14% of the overall study 
cohort scored ‘severe’ stress at baseline and 7% at follow up; and 4% of the overall study 
cohort scored ‘extremely severe’ stress at baseline and 4% at follow up. Responses were 
incomplete for 7% of the overall cohort at baseline and 14% at follow up. 
Table 11. Perceived Stress (stress component of DASS21) between subjects, baseline to F1. 














Intervention 1 14.2 2.0 10.3 18.1 0.007 p=0.9 
 2 12.9 1.9 9.1 16.7 
  
No 
intervention 1 14.3 1.6 11.1 17.5 
  
 2 13.1 1.5 10.0 16.2 
  
 
Table 12. Perceived Stress (stress component of DASS21) between subjects, baseline to F2. 














Intervention 1 16.3 2.4 11.5 21.1 1.19 p=0.3 
 2 11.9 2.2 7.4 16.2 
  
No 
Intervention 1 12.8 1.5 9.8 15.8 
  






4.2.7 Cortisol  
 Cortisol was measured at 0800hrs, 1400hrs and 2000hrs at baseline and follow up, 
one month later. These three readings were averaged to give a single result. Normal reference 
ranges for each test are as follows: 0600 to 0800hrs- 5.5 to 28.9 nm/L, 1800 to 2000hrs – 1.1 
to11.6 nm/L and midnight - <7.0 nm/L. For most participants, this was an unpleasant process, 
as described in another study using salivary cortisol kits (Kalman & Grahn, 2004). 26 case 
participants and 26 wait list participants returned all samples required for comparison. 11 
case participants and 9 wait list participants completed only baseline samples, despite phone 
and message reminders. Two participants (one case and one waitlist participant) completed 
only the follow up cortisol samples. Feedback about performing the cortisol included it was 
difficult to collect and it was extremely unpleasant to chew on the cotton bullet for the length 
of time required to produce a sample. One participant had difficulty generating enough saliva, 
which resulted in one of the three samples being insufficient to measure. One participant had 
significantly abnormal levels of cortisol and this participant’s measures were excluded from 
analysis.  The cortisol assessment was a significant addition to the data collected, as it 
represented the only objective analysis of stress levels. The number of incomplete cortisol 
results does not affect validity of the result.  
Cortisol levels for the intervention group were 7.3 nm/L (95% CI, [5.5 nm/L,9.0 
nm/L]) at baseline and 7.6 nm/L (95% CI, [4.2 nm/L,11.0 nm/L]) at F1. Wait list cortisol 
levels were 5.1 nm/L (95% CI, [3.2nm/L, 6.9 nm/L]) at baseline and 7.6 nm/L (95% CI, 4.0 






Table 13. Mean cortisol of intervention and waitlist group, baseline to F1. 
Intervention Timepoint Mean Std. Error 95% Confidence Interval P-Value 





Intervention  Baseline 7.3 0.9 5.5 9.0 p=0.5 
 F1 7.6 1.7 4.2 11.0  
No 
intervention Baseline 5.1 0.9 3.2 6.9  
 F1 7.6 1.8 4.0 11.1  
 Normal cortisol reference ranges: 0600 to 0800hrs- 5.5 to 28.9 nm/L, 1800 to 2000hrs – 1.1 to11.6 nm/L and midnight - 
<7.0 nm/L. 
 
4.2.8 Quality of life as measured by the MusiQoL  
The MusiQoL self-rating questionnaire is a quality of life tool, developed for and 
validated in the MS population (Simeoni et al., 2008).  Participants were asked to complete 
MusiQoL at baseline, at one-month post face to face session follow up and 6 months post 
face to face session.  Interventional participants scored a mean of 63.9 (95% CI, [58.1, 69.8]) 
at baseline, 67.2 (p=0.3, 95% CI, [61.8, 72.5]) at F1 and 73.3 (p=0.3, CI 95% [66.3, 80.4]) at 
F2. Wait list participants scored 67.3 (95% CI, [62.6, 72,0]) at baseline, 70.8 (95% CI, [66.6, 
75.3]) at F1 and 69.2 (95% CI, [64.7, 73.8]) at F2. At both F1 and F2 the waitlist group had a 
slight improvement of quality of life. Completion rate of this measurement was 84% (n=84).  








Table 14. Mean quality of life (MusiQoL), baseline to F1. 














Intervention 1 63.9 2.9 58.1 69.8 1.11 p=0.3 
 2 67.2 2.7 61.8 72.5 
  
No 
Intervention 1 67.3 2.4 62.6 72.0 
  
 2 70.9 2.2 66.6 75.3 
  
 
Table 15. Mean quality of life (MusiQoL), baseline to F2. 











Bound   
Intervention 1 65.8 3.6 58.5 73.1 0.036 p=0.3 
 2 73.3 3.5 66.3 80.4 
  
No 
Intervention 1 68.5 2.3 63.8 73.2 
  
 2 69.2 2.3 64.7 73.8 
  
 
4.3 Secondary Data Analysis 
Given the presence of several outliers a non-parametric statistical analysis was 
applied to the data, which is more robust to deviations of central tendency due to 
outliers.  Specifically, the difference between the 6-month follow-up and baseline values was 
calculated for each test variable.  A Mann-Whitney-U test was performed to compare 
medians between the intervention and non-intervention groups.  As with the parametric 
analysis an alpha-level of 0.05 was used as the statistical significance threshold. 
In this analysis, median score comparison does reflect a significant effect of 
intervention on the case group for QoL, as demonstrated in figure 5. However, there is no 




Figure 3.  Median change in perceived stress (sVAS) between subjects. 
 
o= outlier, participant 81, 67, 69, 83 and 74 
*= extreme outlier, participant 57 




o = outlier, participants 74 and 57 QoL=quality of life 
Figure 5. Median change in quality of life (MusiQoL) between subjects.  
4.4 Intervention adherence 
Participants were enrolled into this study irrespective of presenting stress levels, and 
half of the participants had normal levels of perceived stress over the course of the study. 
Reducing the cohort to those interventional participants whose levels of stress at baseline 
were moderate, severe or extremely severe, 12% (n=6) participants fell into this category. All 
six participants had improved levels of stress at F1. From an observation perspective of this 
small group two of the six participants had good adherence to performing PMR, i.e. 
performed PMR 5-7 days on average per week. The remaining 4 participants had poor 
adherence to performing PMR, i.e. 0-2 days per week on average. The interventional effect 
for meditation was less related: one of the 6 participants had reasonable adherence to 
performing meditation, i.e. 3-4 days per week on average; and five participants had poor 
adherence to performing meditation, i.e. 0-2 days per week on average.  
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In reverse, the next observation is of those who were adherent to the programme. Of 
the 12 interventional participants (24% of cases) who performed PMR 5-7 days per week on 
average (i.e. good adherence) there was a perceived stress levels remained largely static. Of 
the 14 interventional participants (28% of cases) who performed meditation 5-7 days per 
week on average (i.e. good adherence) 12 stayed the same or improved their level of stress, 
while 2 participants experienced a worsening of their perceived stress. Making the same 
observation using the SVAS, of the adherent participants just over half had improved levels 
of stress. MusiQoL scores for adherent participants were better in 12 participants and worse 
in five. 
Although compromised by adherence analysis of the cortisol levels of both groups 
shows that intervention participants began with higher levels of cortisol than the wait list 
group. By the follow up measurement both groups had increased cortisol levels: although the 
intervention group’s level rose minimally and the wait list group rose by more.  All cortisol 
means remained in the normal reference range at baseline and follow up. 
MusiQoL was completed by 84% of overall study participants. The means of both 
groups improved from baseline to F1 and F2 and both groups mean scores were at the higher 
(i.e. a good quality of life) end of the scale at all time points.  
Adherence with the study intervention was recorded by the attendance to one on one 
sessions with the study investigator and study diary entries to reflect daily practice of SME. 
68% of intervention participants attended 4 of 4 one on one sessions, 4% attended 3 sessions, 





^SME = stress management exercise 
Figure 6. Stress management exercise attendance to education sessions, max. 4 sessions. 
Good adherence to home practice of SME was considered as performing either the 
meditation or PMR five to seven days per week, for 20 minutes per session using the 
provided study CD. Reasonable adherence was recorded as performing PMR and/or 
meditation two to four times per week and poor adherence was considered non-participation 
to one day of PMR and /or meditation per week. 
For F1, 26% and 24% of intervention group had good adherence to the programme of 
performing meditation and/or PMR respectively; i.e. five to seven days per week. For F2, 
24% of the intervention group had good adherence to meditation and PMR.  
  
^SME = stress management exercises 
















No. of sessions attended (max. 4)









PMR 23 9 12 6













^SME = stress management exercise 
Figure 8. Adherence to stress management exercises at F2. 
Reasons for poor adherence were explored by thematic coding. Common themes 
given for not performing the stress management strategies as per protocol were 1) strategy 
dissatisfaction, 2) prioritisation issues, 3) personal stress or distress, and 4) MS or bodily 
symptoms. Strategy dissatisfaction included using one of the strategies as per protocol but not 
the other due to preference for one or dislike for one of the strategies, denied benefit from 
strategy, not feeling stressed enough to perform SME, or SME too hard to perform. 
Prioritisation issues included participants ‘not having time’, ‘too busy’, ‘forgot’, and ‘too 
lazy’. Personal stress or distress included feeling too stressed or too upset to perform SME. 
MS or bodily symptoms included fatigue and pain (in this instance pain was related to 
experiencing spasms during PMR). Although some participants did not respond to this 
question, prioritisation issues represented the most common reason for non-adherence.  
4.5 Qualitative evaluation 
The majority of data analysis undertaken in this study was quantitative. A smaller 
analysis evaluated feedback from participants, collected from baseline and follow up 
0-2 days/week 3-4 days/week 5-7 days/week No responses
PMR 22 5 12 11











questionnaires and from the intervention participant diaries. The areas for thematic analysis 
included ways that study participants self-managed their perceived stress.  
4.5.1 SME Themes and Change in Practice of Managing Stress over Time 
Participants were asked to define their current stress management strategies from a 
16-item list of common stress management strategies. These strategies included exercise, 
prescription medication, drinking alcohol, smoking tobacco, using illegal drugs, regular 
meditation, using mindfulness, CBT, talking to a psychologist, talking to family, talking to a 
general practitioner, talking to the MS team, shopping, spending time with family and/or 
friends, deliberately avoiding the stressor, and doing nothing at all (see tables 6,7 and 8). As 
there was no standardised or validated comprehensive list of stress management strategies 
used in MS, this list was generated by listing the SME under examination in this study, 
standard evidenced-based interventions and referrals for people experiencing psychological 
issues. Additionally, they were asked to add to that list if their usual method of managing 
stress was missing from the choices. The use of these strategies was then described in terms 
of frequency using numbers of study participant utilising that strategy.  The purpose for this 
examination was to see if there was differentiation from within and across the whole study 
population and between baseline and follow up.  
Firstly, the distribution of the 16 strategies was similar between and across the study 
population. The strategy occurring with least frequency was once (‘doing nothing’, case 
group, 1 month follow up) and highest occurring strategy was 28 times (‘exercise’, case 
group, baseline). This thematic grouping was developed further from by delineating the uses 
of strategies into low frequency (less than 10 participants using a strategy at any single time 
point), moderate frequency (10-20 participants using a strategy at any single time point) and 
high frequency (20+ participants using a strategy at any single time point). Throughout the 
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study participants employed the strategies of regular exercise, talking about their stress to 
family members, spending time with family and/or friends and avoiding the stressor with 
high frequency.  Of the medium frequently used strategies included prescription medication 
use, using alcohol, counselling with a general practitioner and shopping. Less frequently 
smoking tobacco or marijuana, using other illegal drugs, meditation, mindfulness, CBT, 
talking or counselling with a professional psychologist, talking or counselling with their MS 
team and doing nothing were employed. 
At follow up some changes in other SME strategies were noted: alcohol was used 
infrequently, meditation, and mindfulness were used at a medium frequency, avoiding the 
stressor reduced frequency to medium use and for the case group only shopping was reduced 
to low frequency use. All other strategies were employed at a similar frequency to baseline. 
Relating to the case participants only, over the course of the study meditation and prescription 
medication were utilised more and ‘doing nothing’ used less by the time of follow up.  
For further SME thematic exploration, the original 16 strategies employed were 
thematically divided into either healthy (or somewhat better ways to manage stress; e.g. 
exercise), not healthy (or somewhat not a better way to manage stress; e.g. using illegal 
drugs) or neither healthy nor unhealthy groups. Each of the identified strategies were 
independently grouped by the principle investigator, the psychologist advising the study and 
the neurologist involved with the MS clinic. More empirical than scientific, the purpose for 
this type of thematic exploration was to determine if other SME types commonly used by the 
study population were in line with what MS specialists were using as part of routine health 
promotion.  Full agreement between the three clinicians (MS nurse specialist, MS specialist 
neurologist and MS specialist psychologist) was found with exercise, 
mindfulness/meditation, CBT, psychology counselling, GP counselling, MS team counselling 
and spending time/talking with family and /or friends for positive health promoting activities 
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for managing stress. Of these, health promoted strategies exercise and spending time with and 
talking to family/friends was employed with high frequency by the study participants. GP 
counselling was utilised with moderate frequency. Mindfulness, meditation, CBT, psychology 
counselling and MS team counselling were used with only a low frequency. Equally, using 
alcohol, smoking tobacco and using illegal drugs were unanimously agreed upon by the 
clinician group as unhealthy stress management strategies and contraindicated in health 
promotion and used with low to moderate frequency by study participants.  
Less well defined and somewhat difficult to achieve consensus on without the benefit 
of context, some stress management strategies were not clearly healthy or unhealthy. These 
strategies in moderation might be perceived as healthy but no frequency or amount was 
recorded. Additionally, the reasons or scenarios around these strategies are unclear. For 
example, if drinking alcohol in moderation happens in the context of meeting friends to talk 
about increased levels of stress, this might be considered a healthy strategy. Alternatively 
drinking to excess on a frequent basis to numb unpleasant sensations or thoughts associated 
with stress is then not considered a healthy strategy for managing stress. The strategies in 
which full agreement was not reached were: using prescription medication, shopping, 
avoiding the stressor and doing nothing. Using prescription medication and doing nothing 
was used in low frequency by the study population; shopping in moderate frequency and 
avoiding the stressor were used with high frequency.   
4.5.2 Participant’s Perception of Change over Time 
59% of participants responded to the more detailed questions of ‘do you think your 
level of stress has improved?’ and ‘why do you think your level of stress has changed?’ The 
chart below shows that at F1 around one quarter of participants felt their levels of stress had 
improved since learning SME. One third of participants felt no change at F1, and 2 




Figure 9. Personal reflection of perceived stress change, baseline to F1.  
 
Figure 10. Personal reflection of perceived stress change, baseline to F2.  
 
4.3.3 Participant Feedback  
Direct feedback for case participants who felt an improvement and those who didn’t 
were shared. Some of the feedback includes: - 
Participant 1-34 at F1 said ‘yes’ to improved levels of stress: “We have had a very stressful 
month (moved to a new house, kids changed day-care, husband going for new job, son is 
currently sick, poor sleep). I am tired and symptomatic but definitely coping. I believe I 
















Case                                                                                   Control
Personal reflection of perceived stress
'Is your level of stress better since starting MindS?'




















Case Group                                                                          Wait List Group
Personal Reflection of Perceived Stress Change Over Time
Case versus waitlist, F2 
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Participant 1-01 at F1 said ‘yes’ to improved levels of stress: “I think I'm accepting that 
sometimes 'shit happens' and I know that it eventually has an end”. 
Participant1-23 at F2 said ‘yes’ to improved levels of stress: “For the most part I believe I am 
handling it better; now I take the time to go through the exercises and also break down the 
stressor and put it aside”. 
Participant 1-20 at F1 said ‘no’ to improved levels of stress: “I still let stress get to me”. 
Participant 1-13 at F1 said ‘no’ to improved levels of stress: “I'm not coping very well, 


















5.1 Executive summary 
PMR, meditation and mindfulness did not significantly reduce stress or improve 
quality of life in the MS cohort. Comparison of mean in each participant group did not show 
evidence of a change between baseline and follow-up.  Hence, these data provide no evidence 
of an intervention effect. This was a consistent result across all measures: sVAS, DASS21, 
MusiQoL and salivary cortisol. Comparison of median in each participant group was 
undertaken due to the presence of outliers and as a result, potential confounding of results. In 
this secondary analysis, there was no significant intervention effect on perceived stress as 
measured by the DASS21, sVAS and cortisol, but there was a significant effect by the 
intervention on quality of life in the case group.   
5.2 Outcomes 
 The primary outcome of the intervention in reducing perceived stress in PwMS was 
not met. When median scores were analysed there was a significant effect of the intervention 
from baseline to F1 and F2 on quality of life, although not for perceived stress or cortisol. For 
perceived stress, this contrasts with the positive outcome of the majority of studies listed in 
the literature review. Quality of life is comparable to the studies using QoL as a measure of 
effect. Cortisol has not been used in previous studies, so this particular result is unique. Direct 
comparison of this study with the literature is difficult because no two studies used the same 
SME technique, were conducted in the same setting or used the same measurement 
assessments. Further augmenting this discussion point is the fact that predominantly positive 
studies reach publication. All but the Mohr (2012) study were small cohorts, not large enough 
to avoid type 1 error. These smaller studies should be replicated in a larger cohort to confirm 
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the intervention effect, which, with the heterogeneity of the study interventions and 
assessments, has not been achieved. Moreover, all of these studies relied on self-rating 
measurements for outcome, reducing reliability of intervention effect further (Artemiadis et 
al., 2012; F. W. Foley et al., 1987; Ghafari et al., 2009; Hughes et al., 2006; Kolahkaj & 
Zargar, 2015; Simpson et al., 2017). This might explain why the intervention effect has not 
been reported to last (Hughes et al., 2006; Mohr et al., 2012; Simpson et al., 2017). The only 
study that showed persistence of effect (of quality of life) was at three months post 
intervention (Ghafari et al., 2009). No study was able to show persistent benefit from 
intervention in reducing perceived stress beyond the face to face sessions. 
5.3 Adherence 
Adherence is a key point for discussion. The current study found adherence to home 
practice of SME difficult. It is interesting that a very recently published study of similar 
nature by Simpson (et al., 2017) also found adherence to be problematic. 60% of study 
participants completed what was considered acceptable number (i.e. 4-8) of group MBSR 
session and further 60% of participants returned adherence data, showing an average of 32.5 
minutes of MBSR practice per day (Simpson et al., 2017) . Reasons given for not attending 
the sessions included bodily pain, work commitments, holidays and ‘slept-in’. Despite this 
they were able to show at the conclusion of the sessions a significant improvement in 
perceived stress, anxiety, depression and self-compassions measures, all evaluated by self-
rating scales. Unfortunately, the study outcome measures were less robust for quality of life. 
Negligible differences were seen for quality of life and perceived stress at 3 months post 
intervention. In comparison to the current study barriers to adherence were similar and 
included bodily symptoms and prioritisation issues. The current study also found strategy 
dissatisfaction and personal distress barriers to adherence.  
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This study and the current study both did not use screening scores of perceived levels 
of stress as inclusion/exclusion criteria.  
5.4 Level of Perceived Stress Versus Measured Level of Stress 
Another observation made for the current study was that many participants considered 
themselves more stressed than their own assessments allowed for. ‘Very’ and ‘really’ stressed 
were descriptions frequently made by study participants at the consent and baseline 
interview. However, baseline levels of stress as measured by the sVAS, DASS21 and salivary 
cortisol indicated that most participant’s levels of stress fell into the normal or only slightly 
higher than normal level of stress. This represents an interesting discord, worthy of further 
analysis. The scope of this study did not prospectively include exploration of this 
phenomenon but possible reasons for this could include cultural and social attitudes to stress, 
as well as personality traits for exaggeration or over reporting. Once again, future studies and 
clinical application of stress management strategies would benefit from prospective 
consideration of this phenomenon.  
The phenomenon of reported (anecdotal and, to a lesser extent, self-rated 
questionnaire) perceived stress being different to biological evidence of stress (cortisol 
levels) is interesting as it raises for discussion the phenomenon of what people perceive as 
stress, the individual response to stress and how stress is reported. The current study did not 
ask participants to define stress but, rather, asked participants to report their current methods 
of managing stress and to perform specific SME. The studies outlined in the literature review 
also did not engage in a closer examination of participants’ understanding of stress.  
Basic emotions: happiness, surprise, fear, disgust anger, and sadness are said to be 
hardwired, largely determined by genetics and evolution (Ekman, 1992).  While basic 
emotions are present at birth more complex emotions and feelings, like stress, continue to 
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develop over a person’s lifetime, affected by experience, cultural and social factors. Recent 
research in the area of emotion development suggests that experiencing emotions to specific 
situations can be a learned outcome (Barrett, 2017).  The next step in this theory suggests 
emotions are attributed to the bodily feelings with reference to experience, culture, gender 
and other factors, but not always to the same emotion for every person. For example, two 
people bungy jumping from the same bungy location on the same day are likely to experience 
similar bodily feelings e.g. sweating, racing heart but one may attribute that experience to 
fear and the other to exhilaration. The same concept may be applicable to perceived stress. 
For example, a looming work deadline for some people will inspire creativity and 
productivity and in others an inability to meet the deadline. This discord between feeling 
overwhelmed by stressors and being objectively stressed might be somewhat explained by 
this theory of complex emotion development.  The learned emotional concepts and learned 
responses to stressors can be manipulated to influence behaviour, for better or worse. Using 
this approach to change health behaviour is the basis of CBT, mindfulness and chronic 
disease management programmes.  
In MS, evidence for achieving health behaviour changes are varied. MS Brain Health 
(Giovannoni et al., 2016) robustly supported health behaviours include keeping physically 
active, keeping weight in normal range, keep one’s mind active, avoiding tobacco smoking 
and limit alcohol to a moderate intake.  Developing interventions that address making health 
behaviour change is influenced by intervention characteristics (e.g. complexity of and manner 
of delivery), individual factors (e.g. existing mental health issues), demographic 
characteristics (e.g. gender, age and socioeconomic status), social and interpersonal factors. 
Barriers to one being able to make changes include poor health literacy, poor general literacy, 
self-efficacy, coping style and personality. On top of these psychosocial and literacy barriers, 
cultural differences also influence a person chance of engaging with positive lifestyle 
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changes. The relationship between the person receiving the education/counselling and the 
person providing the education is also important to its success. Finally, to sustain change the 
effort must persist beyond inevitable difficulties that come over time. Personal motivation 
important to health behaviour change. The current study did not recruit particularly motivated 
participants, in order to reduce selection bias. This recruitment strategy enhanced the realistic 
effect of the intervention and lent an understanding to some of the barriers to this type of 
intervention. The current study protocol addressed some of the issues described above; i.e. 
literacy and practical barriers to participating in the study. Coping style and previous 
response to stressful stimuli were explored for the participant to make changes to future 
exposures to the stressors. Cultural and social barriers were identified with individuals but no 
detailed exploration of this theme was undertaken.  
A recent qualitative study of health behaviour in MS observed there were 5 themes 
contributing to barriers for people with MS to make health behaviour change (Plow & 
Golding, 2016). These themes are 1) roles, priorities and preferences; 2) sense of duty; 3) 
problem of fatigue and mobility; 4) taking control; and 5) resilience. Of the 17 PwMS 
interviewed in focus groups or one-on-one, the experience of having MS, in the context of 
their rest of their lives was usually a motivator for multiple health behaviour change. People 
were more likely to make multiple health behaviour change if they felt they had control over 
the disease, even in the context of persistent symptoms, e.g. fatigue and mobility issues. 
Unfortunately, barriers to making change also stemmed from persistent MS symptoms, like 
fatigue and mobility problems.  While some participants used this knowledge to plan their 
day, allowing for breaks and expecting fatigue, others found this aspect of MS was 
demotivating and they were less likely to participate in activities that in the longer term might 
make their symptoms less debilitating. For the health care professionals delivering health care 
packages that are largely self- monitored and self-administered, this complexity will affect 
78 
 
adherence to programmes. In the setting of the MindS study this observation may go some 
way to explain poor adherence to the performing mediation and PMR. 
 Following on from, and somewhat related to, the previous discussion point is that 
poor adherence may reflect response to the homogenous nature of the protocol.  This was 
evidenced by the fact that the participant who had previous experience with or were at least 
familiar with the concept of meditation and PMR were more likely to adhere to the protocol 
and were using participation in the study as a motivator to return to or enhance their routine 
practice. On the flip side, some participants voiced discomfort performing meditation and/or 
PMR. For example, when the skills were introduced or participant diaries were reviewed for 
compliance some participants said they weren’t comfortable with or hadn’t performed either 
meditation and/or PMR as ‘it really isn’t their thing’.  
Ironically the reason given for some participant’s less than expected intervention 
adherence was they found they were too stressed to perform the stress management strategies 
on a regular basis. On further (but unfortunately brief) discussion and examination of coping 
style these participants were more likely to respond to stressors by ignoring them and pushing 
on with their daily activities. This coping style could represent a group of people that should 
be flagged for additional support in making a health behaviour change.  
5.5 Study strong points 
 In prospectively planning this study, consideration was given to the level of robust 
assessment required to add to the existing literature. The two robust features of this study are 
a larger study cohort and using salivary cortisol for objective measure of intervention effect. 
In design, this study reflected the day to day realities of a largely self-managed intervention, 
and barriers to routinely and regularly performing SME were identified. For successful 
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integration of SME as part of managing modifiable lifestyle factors these barriers should be 
addressed. 
5.6 Study weak points 
This study recruited PwMS, without regard for baseline levels of perceived stress. 
Half of the overall group entered and finished the study with a normal level of stress, 
measured both objectively and subjectively. Recruiting this way eliminated selection bias but 
it is likely that this influenced the outcome. Salivary cortisol testing was completed by half of 
study participants, equally in both groups, although it is not likely to significantly affect the 
study results. The survey was returned by half of the participants at F2, which will affect the 
results. 
5.7 Conclusions to be drawn 
The literature review has shown that increased stress can impact MS, and managing 
stress can improve living with MS. In contrast, the current study has shown that in a random 
cohort PwMS (with a large range of age and disability) performing mindfulness, meditation 
and PMR had no significant effect on perceived levels of stress but may have an effect on 
quality of life. Barriers to performing SME could be thematically categorised into four 
themes of strategy dissatisfaction, prioritisation issues, personal stress or distress and MS or 
bodily symptoms. Non-SME strategies employed by participants included exercise, formal 
and/or non-formal counselling, avoidance tactics and medicating/blocking strategies. 
Emotional behaviour responses, distraction tactics and other relaxation techniques were also 
employed. Future studies should focus on populations of PwMS who have at baseline 







Hi. I am the clinical trials coordinator for the MS clinic. Since you attend the clinic I would 
like to introduce the Mindfully Managing Stress in MS (MindS) study to you. Do you have a 
couple of minutes to talk about the study? 
This study is a local observational study to investigate a stress management intervention in 
MS. The investigator is Susan Agland who is also the clinical nurse specialist for the clinic.  
Would you be interested to learn more about this study? (Offer the PICF to the potential 
participant) 
(If yes) To give you some background on the study: there is growing evidence that stress may 
be associated with increased risk for MS relapse. This study plans to examine people with 
MS’ perceived levels of stress over 6 months once they have participated in a stress 
management intervention.  
Participants will be randomly assigned to be in either the interventional group or the wait list 
wait list group. This means that some will participate in a stress management programme 
and some will be in the wait list group for which the intervention is tested against. 
Participants in the wait list wait list group will be offered the programme if it shows benefit 
in reducing perceived stress and/ or an improvement in quality of life.  
Perhaps you would like some time to consider the patient information and consent form? Is it 
OK for me to forward your name to the investigator to follow up with you?  

















Progressive muscle relaxation from TAMING STRESS IN MULTIPLE SCLEROSIS 
www.mssociety.ca 
Progressive muscle relaxation is often used as an aid to stress management. And, done in bed 
before you go to sleep, it can be an aid to a sound night’s sleep. 
Going through your body’s entire group of muscles – tensing, relaxing, and focusing on the 
changes – will take about 12 to 15 minutes. If it takes less than that, you are moving at a non-
relaxing speed. These exercises will provide the most benefit if you do them twice a day. If 
there are some muscle groups that you cannot work with comfortably, skip them. If you have 
significant spasticity in some muscles, strongly tensing those muscle groups could trigger a 
spasm. You may want to speak with a physiotherapist or other MS health professional about 
ways to work in a more comfortable way. Many people, especially those with cognitive 
problems, find that the exercises are easier to do along with a pre-recorded tape. You can 
prepare the tape yourself or ask someone with a relaxing voice to do it for you. You will work 
with each of 17 muscle groups in a specific order. Tense, but don’t strain each muscle group. 
Hold the tense position for the slow count of five, paying attention to the way those muscles 
feel. Relax the muscles – letting them go totally limp. Focus for a count of five on how the 
muscles feel when relaxed.  
To prepare for the exercise, wear comfortable, loose-fitting clothing, remove glasses or 
contact lenses, and sit up in a chair without crossing your legs or arms. You may also do this 
lying down in bed. 
1 Clench both hands. Focus on how your hands feel and how the tension moves into the 
forearms. Relax. Notice what the muscles in your hands and forearms feel like now. 
2 Touch your fingers to your shoulders. Raise your arms level with your shoulders. Focus on 
the tension in your biceps and upper arms. Relax and focus on the change in feeling. 
3 Shrug your shoulders, raising them as high as possible. Focus on the tension in your 
shoulders. Relax and focus on the change. 
4 Wrinkle your forehead. Notice where tension occurs – around your eyes and forehead. 
Relax and focus on the change. 
5 Close your eyes tightly. Focus on the tension. Relax and focus on the change. 
6 Clench your teeth. Focus on the tension in your jaw, mouth, and chin. Relax and focus on 
the change. 
7 Press as much of your tongue as possible onto the roof of your mouth. Focus on the tension 
in your mouth and throat. Relax and focus on the change. 
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8 Move your head slowly backwards as far as you comfortably can, keeping your shoulders 
level. Focus on the tension in your neck and upper back. Relax and focus on the change. 
Note: If you experience Lhermitte’s sign – an electrical-like shock in your spine when you tip 
your neck forward – skip step 9. 
9 Pull your head forward, down onto your chest. Focus on the tension in your neck, 
shoulders, and upper back. Relax and focus on the change. 
10 Move away from the back of your chair, arch your back and push your arms upward. 
Focus on the tension in your back and shoulders. Relax and focus on the change. 
11 Fill your lungs with air and hold the breath. Focus on the tension in your chest and back. 
Exhale all the way, relax and focus on the change. 
12 Pull your stomach as far back toward your spine as you can. Focus on the tension in your 
stomach muscles and changes in your breathing. Relax and focus on the change. 
13 Without pulling your stomach in, tense your stomach muscles. Focus on the tension. Relax 
and focus on the change. 
14 Tense the muscles in your buttocks. Focus on the tension. Relax and focus on the change. 
15 Flex your thigh muscles by straightening your legs or tensing the muscles. Focus on the 
tension. Relax and focus on the change. 
16 Lift your feet off the ground. Point your toes up, your heels down. Focus on the tension in 
your feet, ankles, and calves. Lower your feet, relax, and focus on the change. 
17 Lift your feet slightly and curl your toes all the way down. Focus on the tension on the top 
of your feet and in your arches. Lower your feet, relax, and focus on the change. 
18 After you have learned to be aware of tension in all 17 muscle groups, you may want to 
focus only on those groups that give you the most trouble. Tense and relax those groups – 
often the jaw, neck, and stomach –several times during the day. Check your “high tension” 
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